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Heart failure (HF) is a highly complex disorder and a major end-point of 
cardiovascular diseases (CVD). The pathogenesis of HF is mostly unresolved but 
involves interplay between cardiac structural and electrical remodelling, metabolic 
alterations, cell death and altered gene expression. Mitochondrial dysfunction and 
HF are common complications of chronic treatment from diverse groups of drugs, in 
particular anticancer drugs such as doxorubicin (DOX). Treatment of animals and 
cardiomyocytes with cardiotoxic chemicals such as β-adrenergic receptor agonists 
(such as isoproterenol) induces cardiac dysfunction and HF.  Previous work done by 
the group have identified the pineal hormone melatonin was protective against 
stress-induced cardiac arrhythmias and simulated heart failure in cardiomyocytes in 
vitro. Melatonin synthesis is also dramatically decreased with age and in patients 
with CVD.  
The aim of the present project was to better understand the pathogenesis of drug-
induced cardiac dysfunction and delineate the role of melatonin in cardioprotection 
in H9c2, a model rat cell line in vitro. Using the Seahorse XF analyser method, it 
was demonstrated that commonly used medication for chronic diseases such as 
amiodarone, amitriptyline, and statins all caused altered mitochondrial dysfunction. 
In addition, cardiotoxic chemicals (isoproterenol, hydrogen peroxide, DOX) altered 
oxidative phosphorylation and glycolysis in living cardiomyocyte-derived H9c2 cells; 
these deleterious metabolic changes were ameliorated by melatonin. Flow-
cytometry and Alamar Blue staining methods demonstrated that DOX robustly 
induced apoptosis in H9c2 cells (~30%) which was reversed by melatonin.  
Doxorubicin-induced stress in H9c2 cells dramatically altered gene expression in 
several key signalling pathways integral in cardiac function and disease. These 
included mitochondrial metabolism (UCP2, PPARɣ, Drp1, Mfn1, Parp 1, Parp2, Sirt3 
and Cav3), apoptosis (Bcl2 and Bcl-xL), cardiac electrophysiology and arrhythmia 
(Scn5a, SERCA2a), calcium handling (SERCA2a) and cardiac remodelling (Myh7, 
ms1). Melatonin pre-treatment attenuated or completely blocked this DOX-induced 
alteration in gene expression in cardiomyocytes. 
In conclusion, the present result demonstrated for the first time that melatonin is 
cardioprotective against drug-induced cardiotoxicity and apoptosis via modifying 
diverse heart failure-related signalling pathways. This provides novel insight on the 
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Introduction   
 
An estimated 7 million people are living with cardiovascular disease (CVD) in 
the UK, with an annual spend of £11 billion on intervention and management 
(BHF report 2012). More than 1 in 4 deaths in the UK are caused by CVD 
(160,000 deaths per year), with a common end-point of sudden cardiac 
death. Deaths from coronary heart disease (CHD) is decreasing dramatically 
each year (BHF report 2012), whereas, counter-intuitively, the prevalence of 
cardiac arrhythmias and heart failure (HF) is dramatically on the increase.  It 
is estimated that 17 million people will have atrial fibrillation, the most 
clinically observed form of arrhythmia, by the year 2030 in Europe, with 
200,000 new cases per year (e.g. Rahman et al., 2014). Heart failure patients 
are also on the increase with an estimated 500,000 sufferers in the UK.  Drug 
treatments for cardiac arrhythmias are limited because of poor efficacy and 
the drugs being pro-arrhythmogenic. Drug treatment for heart failure is also 
limited by long term efficacy, patient-compatibility and organ toxicity (e.g. 
kidney). 
 
In United States (US) and European cohort studies, the lifetime risk of AF is 
22-26% in men and 22-23% in women by age 80 years compared to men. 
The standard risk for a 40-year-old person was 25% (Magnani et al., 2011). 
In the recent years current anticancer therapies are associated with direct 
increased risk of cardiac damage, including left ventricular (LV) dysfunction 
(LVD) and heart failure (HF) (Chen et al, 2012).The Childhood Cancer 
Survivor Study showed that, 15 to 25 years after diagnosis, survivors of 
childhood cancer have an 8.2‐fold higher rate of cardiac death compared with 
the age‐matched and sex‐matched national average. However, compared 
with controls, long‐term childhood cancer survivors had 15‐fold increased 
rates of congestive HF, 10‐fold higher rates of CVD, and 9‐fold higher rates 
of stroke (Yeh et al, 2004; Pinder et al, 2007). Cardiotoxicity induced heart 
failure is becoming more common and has a detrimental effect on the 
population (Armstrong et al, 2014). 
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1.1 Heart Failure 
 
Heart failure is a major public health epidemic worldwide. Heart failure is a 
low cardiac output syndrome characterized by both systolic and diastolic 
dysfunction. The velocity and extent of ventricular contraction and the rate of 
pressure development are decreased in heart failure (Figure 1.1). Left 
ventricular ejection fraction (LVEF) measures the amount of blood being 
pumped out of the left ventricle during each contraction. LVEF is a common 
measurement used to assess heart function although heart failure with 
preserved left ventricular function (Hf-pEF) lies within the normal range. The 
heart failure with reduced left ventricular function (HF-rEF) is usually with 
LVEF less than 35% (Kalogeropoulos et al, 2016). 
 
 
Figure 1.1 Heart failure progression. The cycle of heart failure progression 





The pathophysiological changes occurring through heart failure take in three 
major forms such as LV dysfunction, pulmonary hypertension (PH), and right 
ventricular (RV) dysfunction (Figure 1.2).  
During LV dysfunction there are few pathogenesis mechanisms which result 
in LV dysfunction. The higher volume overload of the heart results in high 
output state causing increased LV dilation and eccentric hypertrophy (Wilcox 
and Yancy, 2016). As a result of the high output it leads to the development 
of heart failure.  
 
 
Figure 1.2: Pathophysiological forms of heart failure. LV, left ventricular; RV, 
right ventricular (Farmakis et al, 2016). 
 
There are several contributing factors towards HF which eventually leads to 
cardiac-related death. Calcium cycling is crucial for both contraction and 
relaxation in cardiomyocytes. During the depolarisation of the cell the 
transverse tubules triggers the entry of small quantities of Ca2+ into the 
cardiomyocyte sarcoplasmic reticulum (SR) membrane (e.g. Stammers et al, 
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2015). The influx of Ca2+ triggers the opening of the nearby calcium release 
channels known as the type 2 ryanodine receptors (RyR2), a large tetrameric 
protein complex. The release of larger quantities of calcium from the 
sarcoplasmic reticulum via RyR2 increases the intracytoplasmic calcium 
which activates troponin C to stimulate the cross bridge formation between 
actin and myosin filaments in sarcomeres to cause cardiac contraction (e.g. 
Santulli et al, 2015).  
On the other hand, sarcoplasmic- endoplasmic reticulum ATPase 
(SERCA2a) initiates cardiomyocyte relaxation by pumping calcium ions from 
the cytoplasm back into the sarcoplasmic reticulum, shutting off contraction 
(e.g. Stary et al, 2016). The SERCA2a activity is regulated by 52 amino acid 
peptide known as phospholamban. In the dephosphorylated state 
phospholamban inhibits the activity of SERCA2a but when it becomes 
phosphorylated by calcium dependent and calmodulin- dependent protein 
kinase (CaMKII),(Nakagawa et al, 2016) SERCA2a becomes activated 
resulting in decrease in cytoplasmic calcium and relaxation occurs. During 
ischaemia the ATP production is reduced which can impair the activity of 
SERCA2a; this was observed in animal models and heart failure patients 
(Gorski et al, 2015). This impairment least favours the calcium being pumped 
back into the SR during diastole thus interfering with both contraction and 
relaxation of the cardiomyocytes (Kho et al, 2015). However in heart failure, 
the diastolic calcium levels increase due to the reduced activity of SERCA2a 
and increased activity of phospholamban. Therefore, SERCA2a activity is 
crucial for calcium cycling handling under normal conditions. In heart failure, 
this process becomes disrupted and the imbalance of the calcium handling 
can have detrimental effects on the heart. 
 
1.2 Functions of the mitochondria 
 
Mitochondria is a double membrane organelle found most in eukaryotic 
organisms.  Mitochondria comprise 25–30% of cell volume across 
mammalian species (Brown et al, 2017), with only the myofilaments being 
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more densely packed within cardiac myocytes. Mitochondria are primarily 
located within subsarcolemmal, perinuclear, and intrafibrillar regions of the 
cardiomyocyte. Mitochondrial dynamics in the form of fission, fusion, and 
autophagy are highly regulated processes that are essential for energy 
production and structural integrity of the organelles (Suliman and Piantadosi, 
2016). The high mitochondrial content of cardiomyocytes is needed to meet 
the enormous energy requirement for contraction and relaxation (which is 
also an active process). About 90% of cellular ATP is utilized to support the 
contraction–relaxation cycle within the myocardium (Opie, 1998).  
The ‘myocardial power grid’ consists of mitochondrial ATP supply that 
transfers energy throughout the cell along intracellular phosphotransfer 
buffering systems. Mitochondria utilize carbon sources from food substrates, 
which are catabolized and passed through the Krebs cycle and are then 
channelled through a series of redox reactions along the inner mitochondrial 
membrane. The oxidation of these substrates creates a proton 
electrochemical gradient, predominantly in the form of mitochondrial 
membrane potential (Mitchell, 1961). Protons that reenter the mitochondrial 
matrix through complex V (mitochondrial ATP synthase) liberate energy that 
phosphorylates ADP, regenerating ATP (Thomas and Gustafsson, 2013). 
However, when there is a dysregulation in the mitochondria, the highly 
regulated processes that are essential to maintain structural integrity and 
energy production fails. Mitochondrial dysfunction arises partly due mutations 
in the mitochondrial DNA that code for mitochondrial components. They may 
also result from the adverse effects of drugs, infections and other 
environmental causes. Abnormal mitochondria are a major source of reactive 
oxygen species (ROS) production, which can induce cellular damage. 
Cellular ROS production occurs when ROS formation outpaces or exhausts 
compensatory signals and overwhelms endogenous scavenging systems 
(Aon et al, 2010; Brown et al, 2013; Murphy and Steenbergen, 2008). ROS 
are produced at several different sites within cells, both within and outside of 
mitochondria (Murphy and Steenbergen, 2008; Nabeebaccus et al, 2011). 
Mitochondrial ROS production occurs at various sites along the inner 
mitochondrial membrane as well as in the mitochondrial matrix by 
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components of the ETC and the Krebs cycle, respectively. ROS (and other 
associated reactive intermediates) can damage proteins and lipids, trigger 
cell-death cascades, and evoke synchronized collapses in the cellular energy 
grid (Zorov et al, 2006; Aon et al, 2006; Orr et al, 2013). 
Abnormal mitochondria can promote programmed cell death through the 
release of cytochrome c into the cytosolic compartment and activation of 
caspases. Apoptosis occurs in two different pathways. The extrinsic pathway 
utilizes cell-surface death receptors and links external stimuli to intracellular 
apoptotic cell death machinery. The intrinsic pathway involves the 
mitochondria and endoplasmic reticulum, which, again, sense stimuli and 
transduce signals to execute apoptosis via another distinct set of molecules 
(Degterev et al., 2003). Therefore, mitochondria directly influence ongoing 
cell injury and death. Mitochondrial abnormalities have also been implicated 
in aberrant cellular calcium homeostasis, vascular smooth muscle pathology, 
myofibrillar disruption, and altered cell differentiation, all important issues in 
cardiovascular disease, including HF. 
Drugs can have adverse effects on the mitochondrial function. Doxorubicin, 
Statins, Rosiglitazone, Amitriptyline and Amiodarone are among the 
frequently used drugs to manage a variety of diseases which have been 
known to cause mitochondrial dysfunction in chronic use. Doxorubicin (DOX) 
is an anthracycline commonly used in cancer treatment. The cardiotoxicity 
caused by DOX could be acute (hours to days) to intermediate (weeks and 
months) and late onset (>12 months) and even years after treatment has 
finished. However, its clinical use is greatly restricted by the development of 
cardiomyopathy and clinical congestive failure (Liu et al, 2008). Statins 
(HMG-CoA reductase inhibitors) are a class of lipid lowering drugs used in 
treatments for hypercholesterolemia and reduce cardiovascular diseases. 
Statins competitively inhibit the conversion of HMG-CoA to mevalonate, a 
precursor for cholesterol synthesis (Herninger and Fritz, 2017) thereby 
eventually reducing the cell’s intrinsic cholesterol synthesis and favouring the 
uptake of serum LDL cholesterol. On the other hand, statins are known to 
promote muscle weakness during prolonged time periods. Statin therapy is 
associated with decreased myocardial function and increase risks of stokes 
21 
 
(Lim et al, 2013). Rosiglitazone is a thiazolidinedione antidiabetic drug used 
in treating type 2 diabetes mellitus. It works as an insulin sensitizer, by 
binding to the peroxisome proliferator –activated receptor in cells and making 
the cells more responsive to insulin. Its use has dramatically decreased over 
the years due to association of increased risks of heart attacks and deaths 
(Varga et al, 2015; Pharaon et al 2017).  
Amitriptyline is tricyclic antidepressant used to treat mainly depressions and 
other anxiety disorders. This drug has significant adverse effects on the heart 
as it causes disturbances in the rhythm of the heart, QT prolongation, leading 
to cardiac dysfunction (Zima et al, 2008; Arici et al, 2013). Amiodarone is a 
potent antiarrhythmic agent that is used to treat ventricular arrhythmias and 
atrial fibrillation. Chronic use of amiodarone induces multiple organ toxicity 
via reduced phospholipid degradation which leads to its accumulation and, 
consequently lipid peroxidation, ROS generation, and disturbance of cellular 




















1.2 Melatonin  
 
Melatonin was initially discovered by Lerner and colleagues in late 1950s, 
which acted as a robust endocrine signal that can regulate the circadian time 
and day length. It is produced from the pineal gland located behind the third 
cerebral ventricle of the brain (Figure 1.3) (Johnstone and Skene, 2015). In 
1950s, Lerner and his co-workers discovered melatonin as a potent 
lightening agent. Melatonin was isolated from beef pineal glands and was 
injected into the frog skin, followed by incubation in in vitro. The result 
showed the frog melanocytes were lightened when melatonin was injected 




Figure 1.3. The neuroendocrine connection between the pineal gland and the 
brain (Dominguez-Rodriguez et al, 2012). 
 
Melatonin can influence both daily and seasonal rhythms in many species.  
The daily rhythmic production of melatonin is a conserved characteristic in 
mammalian physiology (Figure1.4). It is present in higher levels during the 
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night and minute levels during the day (Ganguly et al, 2002). This 
phenomenon was understood in late 1990s, when Maywood and colleagues 
observed in Syrian hamsters, where melatonin mediates the seasonal 
response to photoperiod within the medio-basal hypothalamus (MBH), 
specifically via the melatonin (IMEL) binding sites found in the dorsomedial 
nucleus (DMN).  The distributions of androgen receptors with IMEL sites 
have distinct regions of overlap in adult male hamsters. Together, the results 
indicate there are regions which are responsive to both gonadal steroids and 
melatonin which may regulate seasonal reproduction in GnRH release and 
melatonin influences the sensitivity of the steroidal feedback on cells 




Figure 1.4: Seasonal rhythmic production of melatonin.  
Light perceived through the retinal photoreceptors (PR), and transmitted 
through the retino-hypothalamic tract (RHT), affects mammalian reproduction 
via a complex pathway that involves the pineal, the suprachiasmatic nucleus 
(SCN) of the hypothalamus (HYP), the paraventricular nuclei, (PVN), superior 
cervical ganglion (SCG), and the pituitary gland. Hormones secreted include 
gonadotropin releasing hormone (GnRH) from the hypothalamus, luteinizing 
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hormone (LH), and follicle stimulating hormone (FSH) from the pituitary, 
which affects gonadal activity (Sengupta, 2011). 
 
 
1.2.1 Melatonin Synthesis 
 
Circulating melatonin is synthesised in the pineal gland however local levels 
of melatonin in the eye is synthesised by the retina. In most mammalian 
species the circadian rhythmic system of the pineal melatonin synthesis is 
due to poly-synaptic pathway linking the pineal gland to the hypothalamic 
SCN, which is the origin of the master mammalian circadian clock. From the 
SCN, the neurones pass via the paraventricular nuclei, to the upper thoracic 
intermediolateral cell column of the spinal cord and then sympathetic 
neurones of the superior cervical ganglion, innervates the pineal. As a result 
this activates arylalkylamine-N-acetyltransferase (AA-NAT), a key enzyme in 
melatonin synthesis pathway. The increase in AANAT activity results in an 
increase in the intracellular concentration of N-acetyl serotonin where there is 
a transfer of a methyl group to the 5-hydroxy group of N-acetylserotonin 
which is then converted to melatonin (N-acetyl 5-methoxytryptamine; MEL) 
by hydroxyindole-O-methyltransferase (Figure 1.5) (Pevet, 2014; Erren and 






Figure 1.5: Melatonin synthesis in the pineal gland (Henry, 2015). 
 
 
1.3 The circadian timing system 
 
The human circadian system allows an organism to predict the daily 
environmental changes taking place. Many physiological factors such as 
temperature, hormones and electrolytes along with behavioural changes 
such as mood, sleep, performance and alertness are maintained through 
circadian rhythms (Skene and Arendt, 2006).  Circadian rhythms are rhythms 
that are endogenously generated and synchronized to 24h day by the 
light/dark cycle, to regulate physiological factors in an organism.  In the 
absence of light/dark cycle the circadian rhythms become desynchronized 
from the 24h day, resulting in dysregulated clock system, affecting many 
other physiological factors (Hu et al, 2016).  
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The circadian system involves a circadian oscillator, a photodetector and an 
output signal. These elements together with neural connections link to the 
melatonin rhythm generating system. This is important with regards to the 
regulation of melatonin production and functions (Johnstone and Skene, 
2015). In the melatonin rhythm generating system the oscillator regulating the 
pineal gland function is found in the SCN which can control the stimulations 
of the pineal gland in 24hr basis. Light plays an important role in activating 
the SCN clock via the photoreceptors in the retina and the retinal 
hypothalamic tract (Emens and Burgess, 2015) as shown in Figure 1.6.  It 
stimulates the pineal gland and influences AANAT activity for melatonin 
synthesis. Melatonin transmits the internal time information throughout the 
body to allow regulation and providing feedback information to the brain (Tan 
et al, 2015).  
 
 
Figure 1.6: Pineal melatonin synthesis and AANAT activity is dependent on 
the daily light:dark cycle Arylalkylamine N-acetyltransferase (AANAT), 






The role of melatonin in synchronisation of the circadian system was first 
observed in rat circadian rhythms.  Redman and colleagues demonstrated 
the daily administrations of melatonin can entrain free running circadian 
activity rhythms in rat. When the injections were stopped, the activity rhythms 
became free running again. The onset of the circadian activity coincided with 
the time of the daily injections (Redman et al, 1983). This suggests time of 
day is crucial for melatonin administration to synchronize the circadian 
rhythms. Melatonin is a potent synchronizer of rat circadian rhythms and 
has a direct action on the circadian pacemaker (Armstrong, 1989). 
 
 
1.4 Molecular basis of the circadian clock 
 
The molecular mechanisms underlying the circadian timing system are 
controlled by clock factors and clock controlled genes. The circadian-drive of 
clock genes are primarily expressed through self-sustaining interactive 
intracellular transcriptional/translational feedback loops (Figure 1.7). During 
the subjective day, certain key clock genes are transcribed (e.g. Per1, Per2, 
Per3, Cry1, Cry2 and Reverbα) by heterodimeric complexes of CLOCK and 
BMAL1 (Peschke et al, 2015). This continues till subjective night until the 
levels of PER/CRY proteins become sufficiently high enough to suppress the 
activity of CLOCK/BMAL1 activation. During early morning, the levels of 
PER/CRY starts to decline allowing the transcription of genes to take place. 
Specifically the gene transcription of AANAT (clock controlled gene) occurs 
at this time point which is crucial for the synthesis of melatonin hormone. The 
diurnal rhythm of AANAT activity and melatonin synthesis in the pineal gland 
of vertebrates is controlled by the circadian clock and synchronized by 
environmental photic and thermal signals. This is the negative feedback loop 
of the system and the cycle continues. On the other hand, there is a 
secondary loop which is controlled by Reverbα and Reverbβ which can 
supress Bmal1 transcription. At the end of the night the REVERB proteins 
starts to disappear and Bmal1 peaks, therefore this can be seen as a positive 
feedback loop of the system (Erren and Reiter, 2015; Peschke et al, 2015; 




Figure 1.7: The transcriptional regulation of clock genes in mammals. (A) Circadian interlocking loops show that a primary loop of 
CLOCK-BMAL1 and PER-CRY complexes and an additional feedback loop of ROR/REV-ERB, conferring a tight transcriptional 
regulation. (B) Transcription of BMAL1 and CLOCK is regulated by ROR and REV-ERB through binding RORE elements at their 
promoters (Cho, 2012). 
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1.5 Role of melatonin in cardiomyocyte mitochondrial function 
 
The regulatory role of melatonin in circadian and seasonal rhythms is well 
established (Acuna et al, 1986), and it is known as the chemical expression 
of darkness (Reiter, 1993). However, there is increasing evidence showing its 
involvement in many other functions, involving the role as a powerful anti-
oxidant. Melatonin was first demonstrated to be a direct scavenger of 
oxidants by Tan and colleagues using an in vitro system, this group found 
that melatonin directly scavenged the highly toxic ̇OH (Tan et al, 1993). Li 
and colleagues provided the first evidence that melatonin neutralized ̇OH in 
vivo (Li et al, 1997). Furthermore, Bromme and colleagues supported the 
finding for administration of melatonin reduced ̇OH generated during cerebral 
ischemia‐reperfusion (Bromme et al, 2000). 
In the mitochondria the electron transport chain generates ATP via the 
reduction of oxygen to water, however certain percentage of oxygen can be 
reduced by dissipating single electrons to produce free radicals. The most 
abundant ROS production is from superoxide anion radical (O2-) from the 
electron leakage from oxygen molecule (Erdemli et al, 2016).  Multiple 
electron transfer leading to other ROS generation is negligible, but, 
secondarily, peroxynitrite anion (ONOO−, formed from O2− and nitric oxide, 
NO), hydroxyl radical (OH, formed via H2O2 from superoxide dismutation), 
carbonate radical (CO3−, formed from OH and HCO3 −, or from 
ONOOCO2 − decomposition), and nitrogen dioxide (NO2, formed 
from peroxynitrate, ONOOH or ONOOCO2 −) are generated. These other 
ROS and RNS (reactive nitrogen species) have a much higher reactivity than 
O2− (Pandi-Perumal et al, 2013; Tan et al, 2015; Manchester et al, 2015).  
Generally higher concentrations of these free radicals can mediate cellular 
damage in components such as DNA, lipids and proteins in the mitochondria 
(as it is the origin of ROS production). Free radical damage can be seen as 
oxidative stress which can lead to cell death, senescence or tumorigenesis 
(Andrabi et al, 2015). On the other hand melatonin benefits the cell against 





Figure1.8: Actions of melatonin exerts its effects through both membrane 
and nuclear receptors. At the mitochondrial level melatonin increases its 
efficiency as an antioxidant by reducing free radical generation and 
increasing ATP production (Reiter et al, 2010). 
 
Oxidants are detoxified, antioxidants are stimulated, pro-oxidants are 
suppressed, and prevention of free radical formation can be seen with 
melatonin. Melatonin administration in cells increases respiration and the 
activity of the complexes I to complex IV in the ETC. The physicochemical 
nature of the reaction between melatonin and free radicals has been 
investigated. Three mechanisms have been proposed and tested, including 
single electron transfer, hydrogen atom transfer, and radical adduct formation 
(Paredes and Reiter, 2010; Galano et al, 2011) Using In vitro cell‐free system 
in the presence of one‐electron oxidants, ONOO−, or alkoxyl radicals, several 
studies found that single electron transfer and hydrogen atom transfer were 
important characteristics of the antioxidant activity of melatonin (Mahal et al, 
1999).In the presence of ̇OH, however, radical adduct formation seems to be 
the major mechanism by which melatonin detoxifies ̇OH. This property is not 
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observed in other antioxidants therefore melatonin can both participate in 
electron transport and act as an antioxidant.  
Within the cell melatonin is localized in subcellular compartments such as the 
nucleus, cell membrane and mitochondria to scavenge free radicals (Sarihan 
et al, 2015).  When melatonin detoxifies the OH- (free radical), it is converted 
to cyclic 3-hydroxymelatonin, which is also a potent radical scavenger. Cyclic 
3-hydroxymelatonin is an intermediate metabolite of melatonin and it 
undergoes oxidation resulting in the formation of N1-acetyl-N2-formyl-
methoxykynuramne (AFMK).  Deformation of AFMK leads to the generation 
of N2-acetyl-5-methoxykynuramine (AMK). These compounds are also major 
melatonin metabolites with a similar potency to melatonin in detoxifying ROS 
and reducing oxidative stress. The sequence of scavenging ROS by 
melatonin and its metabolites is known as melatonin's antioxidant cascade 
(Mukerjee et al, 2015; Giacomo and Antonio, 2007; Barthi et al, 2014).   
In addition to its free radical scavenging capacity which protects mitochondria 
from oxidative damage, melatonin also exerts its protective effect on 
mitochondria by direct involvement in membrane integrity, permeability 
transition pore, electron transport, and ATP production. Garcia and 
colleagues first demonstrated that melatonin helped maintain mitochondrial 
membrane integrity and MPTP in vitro using a microsomal system (Garcia et 
al, 1999). Melatonin was further shown to interact with mitochondrial ETC. 
Complexes I and IV to promote electron flux under basal conditions to 
increase ATP production (Martin et al, 2002). The high redox potential of 
melatonin (−0.98 V) was postulated to facilitate the electron transfer in the 
ETC., by donating an electron to complex I of the ETC (Reiter, 2000). 
In conclusion the potential mechanisms or approaches by which melatonin 
interacts with mitochondria are listed (i) Melatonin directly detoxifies 
ROS/RNS through its nonreceptor‐mediated free radical scavenging 
capacity, thereby lowering damage to mitochondrial proteins and DNA 
(Acuna et al, 2002) (ii) Melatonin increases the activity of antioxidative 
enzymes while suppressing pro‐oxidant enzymes in mitochondria (Acuna et 
al, 2005; Inarrea et al, 2011) (iii) Melatonin stabilizes the mitochondrial inner 
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membrane, thereby maintaining mitochondrial integrity (Garcia et al, 1999) 
(iv) Melatonin increases the activity of mitochondrial electron transport chain 
(ETC.) complexes and improves mitochondrial respiration and ATP 
production, thereby reducing electron leakage and ROS generation (Martin et 
al, 2000) (v) Melatonin may directly control the currents through the 

























Heart failure is predominantly caused by cardiovascular conditions such as 
hypertension, coronary heart disease and valvular heart disease, it can also 
be an adverse reaction induced by drug therapy. In addition, some drugs 
have the propensity to adversely affect haemodynamic mechanisms in 
patients with an already existing heart condition. Most non-cardiac drugs are 
known to be associated with the development or worsening of heart failure 
and cardiac function (Swift et al, 2006).The drug-mediated effects act on 
cardiac preload, cardiac afterload or myocardial contractility. Drugs that 
increase cardiac preload or cardiac afterload may have unfavourable effects 
on ventricular function, because increased cardiac preload or afterload 
intensifies the demand on ventricular performance. The ability of the heart to 
comply with this increased demand will depend on pre-existing ventricular 
function.  
Moreover, drugs that may adversely affect heart function without precipitating 
overt symptoms or signs of heart failure are also evident. Example of these 
drugs include anticancer agents such as, mitoxantrone, cyclophosphamide, 
fluorouracil, capecitabine and trastuzumab; immunomodulating drugs such 
as interferon-alpha-2, interleukin-2, infliximab and etanercept; antidiabetic 
drugs such as rosiglitazone, pioglitazone and troglitazone; antimigraine drugs 
such as ergotamine and methysergide; appetite suppressants such as 
fenfulramine, dexfenfluramine and phentermine; tricyclic antidepressants; 
antipsychotic drugs such as clozapine; antiparkinsonian drugs such as 
pergolide and cabergoline; glucocorticoids; and antifungal drugs such as 
itraconazole and amphotericin B. NSAIDs, including selective cyclo-
oxygenase (COX)-2 inhibitors (e.g. Ibuprofen), are included as a result of 
their ability to cause heart disease, particularly in patients with an already 
existing cardiorenal dysfunction (Solard and Spidsted, 2006).  
Amongst these classes of drugs, a group of particular concern are the anti-
cancer chemicals called Anthracyclines such as doxorubicin (DOX) (Swift et 
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al, 2006). Doxorubicin and its derivatives may cause cardiomyopathy in a 
disturbingly high number of exposed individuals, who may develop symptoms 
of insidious onset several years after drug therapy. The risk seems to 
encompass all exposed individuals, but data suggest that children are 
particularly vulnerable. Thus, a high degree of awareness towards this 
particular problem is warranted in cancer survivors subjected to 
anthracycline-based chemotherapy.  
Cardiotoxicity is defined as occurrence of heart electrophysiology dysfunction 
or myocardial damage, as a result the heart weakens and is unable to pump 
blood around the body efficiently.  Cardiotoxicity is one of the most important 
adverse reactions of chemotherapy, leading to a significant increase of 
morbidity and mortality, where 35%-43% of patients had developed clinical 
symptomatic heart failure after doxorubicin treatment (McGowan, 2017). 
Cardiotoxicity can appear early or late in the course of the disease, and since 
the most typical sign of chronic cardiotoxicity is a subclinical, asymptomatic 
systolic or diastolic cardiac dysfunction that can lead to irreversible heart 









Figure 1.9: Changes occurring in the heart at different stages after induced 
by drugs, leading to cardiovascular dysfunction (Madonna, 2017). 
 
Drug-induced cardiotoxicity can lead to diverse cardiac dysfunction. 
Cardiomyopathy is when heart muscle becomes weakened, enlarged, 
thickened, or stiff. This can lead to changes in disturbances in heart rhythm 
and ultimately to heart failure. Myocarditis is inflammation (swelling) of the 
heart which can also lead to changes in heart rhythm and decrease in heart 
performance. Pericarditis is inflammation (swelling) of the sac surrounding 
the heart which can cause chest pains and decreased in cardiac 
performance. Cardiotoxicity can also lead to acute coronary 
syndromes which are caused by blood vessel damage and, reduces blood 
flow to the heart. This can cause chest pains and in severe cases myocardial 
infarction. Chemotherapy can cause acute severe damage to the heart and in 
some cases can lead to congestive heart failure (CHF) in the first year of 





1.7 Cardiotoxicity and cardiomyocyte apoptosis 
 
Chemotherapy-induced cardiotoxicity (such as the use of DOX) can lead to 
cardiomyocyte cell death and irreversible heart damage. Therefore 
pharmacological intervention of apoptosis pathways may represent a 
promising therapeutic strategy for a number of cardiovascular diseases and 
disorders including myocardial infarction, ischemia/reperfusion injury, 
chemotherapy cardiotoxicity, and end-stage heart failure (Mitry et al, 2016). 
Two noteworthy apoptotic pathways (i.e. pathways that in the end prompt to 
action of executioner caspases), the "extrinsic" and "intrinsic" cascades, 
transduce apoptotic signals in mammalian cells.  The extrinsic pathway 
utilizes cell-surface death receptors and links external stimuli to intracellular 
apoptotic cell death machinery. The intrinsic pathway involves the 
mitochondria and endoplasmic reticulum, which, again, sense stimuli and 
transduce signals to execute apoptosis via another distinct set of 
molecules (Degterev et al., 2003). Figure 1.10 summarizes the interlinked 
pathways of the extrinsic and intrinsic apoptotic cascades. 
 
1.7.1 Intrinsic Apoptotic Pathway 
 
The intrinsic pathway transduces extracellular and intracellular stimuli, 
including nutrient depletion, radiation, hypoxia, oxidative stress, ischemia-
reperfusion, and DNA damage. Direct signaling from each of these is 
unclear, but they converge on the pivotal event of mitochondrial outer 
membrane permeabilization (MOMP) (Saelens et al., 2004). At the 
mitochondria, MOMP often follows dissipation of the mitochondrial inner 
transmembrane potential, which may involve opening of the mitochondrial 
permeability transition pore. A separate mechanism for MOMP involves 
members of the Bcl-2 family of proteins acting at the outer mitochondrial 
membrane. Bcl-2 (the mammalian homologue of ced-9) is the prototype of 
the important family of genes in this intrinsic pathway of apoptosis, upon 
apoptotic stimuli, they undergo conformational change, oligomerise and 
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translocate to the mitochondrial outer membrane, promoting MOMP (Green 
and Kroemer, 2004).  
 
Figure 1.10: The Apoptotic Cascade exhibiting the extrinsic and intrinsic 
pathways. Cyt c, cytochrome c; DAG, diacylglycerol; ERK, extracellular 
signal-regulated kinase; FADD, Fas-associated death domain; FAK, focal 
adhesion kinase; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol 
bisphosphate; PIP3, phosphatidylinositol trisphosphate; PLCβ, 
phospholipase C β; PKA, cyclic AMP-dependent protein kinase; PKC, protein 




Nuclear protein TR3 also binds Bcl-2 and promotes MOMP (Zhao et al., 
2006). Histone 1.2, released from the nucleus after DNA damage, triggers 
MOMP – again via an interaction with Bcl-2 family members. After MOMP, 
critical apoptogens (eg, cytochrome c) are released from the mitochondrial 
intermembrane space into the cytosol (Strasser, 2005). When in the cytosol, 
cytochrome c binds to the adaptor protein, Apaf-1. Apaf-1 oligomerizes into 
an apoptosome, which recruits and activates caspase-9. Like DISC in the 
extrinsic pathway, recruitment of caspase-9 in the apoptosome is dependent 
on ‘‘death domain motifs’’ on both caspase-9 and Apaf-1 (Cain et al., 2000). 
As with caspase-8, activated caspase-9 activates downstream effector 
caspases and leads to the execution phase of apoptosis. 
 
 
1.7.2 Extrinsic Apoptotic Pathway 
 
In the extrinsic pathway, death ligands (such as FasL) act and bind with their 
various cell-surface death receptors (such as Fas ligand receptor), 
reorganizing the inactive receptor and stimulating the enlisting of adaptor 
proteins [such as Fas-associated via death domain (FADD)], that 
successively recruits procaspase-8 into a multiprotein complex referred to as 
the death inducing signalling complex (DISC) (Walczak and Krammer, 2000). 
Cluster of those interacting proteins inside the DISC promotes auto 
proteolytic process and activation of the caspase-8 by elicited proximity 
(Igney and Krammer, 2002). In cells, processed caspase-8 is enough to 
activate the opposite downstream effector caspases directly, resulting in the 
execution section of caspase-mediated cell death, caspase-8 mediates 
cleavage of the proapoptotic Bcl-2 family member, Bid, which afterwards 
releases mitochondrial proapoptotic factors (Fulda and Debatin, 2006), 






1.8 Doxorubicin – induced cardiotoxicity and heart failure 
 
In pathophysiological conditions, heart failure may result from drug-mediated 
effects on cardiac preload, cardiac afterload or myocardial contractility. Drugs 
that increase cardiac preload or cardiac afterload may have unfavourable 
effects on ventricular function, because increased cardiac preload or 
afterload intensifies the demand on ventricular performance. Among the most 
cardio toxic drugs, doxorubicin is a well-known anti-cancer drug known or 
inducing cardio toxicity in heart. Many studies over the past had reported 
cancer survivors aged from 4 to 20 years after doxorubicin treatment > 60% 
observed significant decreases in fractional shortening and ejection fractions 
(Mitry and Edwards, 2016).  
Doxorubicin, also known as Adriamycin or Rubex, is an anthracycline 
antibiotic that was isolated from a mutated strain of streptomyces peucetius 
bacterium (Arcamone et al, 1969). Doxorubicin operates on many levels by 
different molecular mechanisms as well as an interaction with iron, 
disconcerting calcium homeostasis, altering the activity of intracellular or 
intra-mitochondrial oxidant enzymes, and binding to topoisomerases 
promoting their dysfunction (Arcamone et al, 1969). 
Doxorubicin is among the most frequently used anthracyclines included in 
chemotherapeutic regimens, to treat broad spectrum of cancers. The 
anthracyclines are antibiotic agents which antineoplastic action results from 
the inhibition of the nucleic acid synthesis by binding to both strands of the 
deoxyribonucleic acid (DNA) helix. This binding prevents normal function of 
the ribonucleic acid (RNA) and DNA polymerases (Takemura and Fujiwara, 
2007). The introduction of the anthracyclines has contributed considerably to 
the improvement of survival in patients with cancer. However, anthracycline-
induced cardiotoxicity is a well-known adverse effect of this category of drugs 
and a major limitation to the total dose that can safely be administered. 
(Rhoden et al, 1993.).  
Based on the dose-dependency of the anthracycline-induced impairment of 
left ventricular function, an upper limit of the cumulative dose of 550 mg/m2is 
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generally recommended. When this upper limit of the cumulative dose is 
exceeded, early heart failure may develop in about 30% of the patients 
receiving these high dosages (Rhoden et al, 1993). In a study among 201 
children who had completed chemotherapy with anthracyclines, decreased 
fractional shortening on echocardiography was present in more than 60% of 
the patients who had received >500 mg/m2and were followed up for at least 
10 years (Steinhers 1991). A retrospective analysis revealed that 30-year 
childhood cancer survivors had a 15-fold higher rate of heart failure and 10-
fold higher rate of other cardiovascular diseases when compared to 
estimated values in their siblings. Cardiac abnormality can be seen as 
asymptomatic disturbances in cardiac rhythms, changes in blood pressure, 
thickening of pericardium, cardiac dilation, and cardiomyopathy 
(Angsutararux et al, 2015; Lestuzzi, 2010). 
 
 
1.8.1 Oxidative Stress: a key mechanism in doxorubicin-induced 
cardiotoxicity 
  
Generally, DOX induces cardio toxicity by exerting effects on the 
mitochondria with increased reactive oxygen species (ROS) production. 
Usually, mitochondria are the site where most of ROS are synthesised as a 
consequence of electrons escaping from electron transport chain and 
captured by oxygen, rendering it to be the site of superoxide production. 
Enzymes among mitochondria, as well as NADPH enzyme (also called 
NADPH dehydrogenase), cytochrome P-450 reductase, and xanthine 
oxidase (XO), will rework DOX and alternative anthracyclines within the sort 
of quinone to semiquinone via one electron reduction of the quinone moiety 
in ring C (Schimmel et al, 2004). In mitochondrial electron transport 
chain, oxygen free radical is also generated when an electron is transferred 
from NADH to oxygen molecule by NADH-ubiquinone oxidoreductase or 
complex I. Thereafter, the free radical undergoes a dismutation, a reaction 
that is accelerated by SOD enzyme, generating less-reactive specie 
hydrogen peroxide (H2O2), which can be detoxified by catalase or glutathione 
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peroxidase (GPx) in the presence of glutathione GSH (Kalivendi et al, 
2001).Oxygen free radical (O2-) may react with H2O2 and form the highly 
reactive hydroxyl radical (OH-) by Haber-Weiss reaction. Under stress 
conditions, O2- facilitates the release of free iron from iron-containing 
molecules, for example, [4Fe-4S]-containing enzymes, leading to the 
generation of OH- from Fenton reaction. Moreover, O2- can facilitate 
the OH- production in the reaction by generating ferrous iron (Fe (II) from the 
reduction of ferric (Fe(III) (Angsutararux et al, 2015). This reactive ·OH can 
oxidize membrane lipid and subsequently generates lipid radicals e.g., 4-









Figure 1.11: A redox cycling of Doxorubicin. 
Redox cycling between the quinone and semiquinone shapes (ring C) of 
doxorubicin (DOX) winds up in oxygen radicals frame Cardiac myocytes, 
which speak to ~85% of aggregate heart mass, are the real contracting cells 
in the heart. In the previous decade, real advance has been made toward 
understanding the apoptosis instruments in cardiomyocytes. Cardiomyocyte 
apoptosis is an exceedingly controlled process; pharmacological intercession 
of apoptosis pathways may speak to a promising helpful technique for 
various cardiovascular illnesses and clutters including myocardial dead 
tissue, ischemia/reperfusion damage, chemotherapy cardiotoxicity, and end-









The interaction between DOX and iron have been known since 1980, when 
the first studies demonstrated that DOX had a strong affinity for iron (Tsai et 
al, 2000) and that the iron complex could cause lipid peroxidation through its 
interactions with the negatively-charged membranes (Chau et al, 2002). DOX 
reduction in the presence of free iron also sets up a cycle for free radical 
generation (redox recycling) and the metabolite doxorubicinol (metabolite of 
doxorubicin metabolised by aldoketoreductase) is known to interact with thiol 
groups on proteins, compounding the damages to the cell (Haghikia et al, 
2014). More recent studies have suggested that the effects of DOX on iron 
metabolism are not mediated by doxorubicin–iron interactions, but rather via 
the proteins that sequester and bind intracellular iron. One such mechanism 
involves the doxorubicinol metabolite forming complexes with the Fe–S group 
the cytoplasmic aconitase/IRP-1 (iron regulatory protein), thereby enhancing 
the stability of transferrin mRNA and preventing translation of iron 
sequestration proteins (Monti et al, 2013). The subsequent decrease in IRP-1 
leads to an increase in free iron, which could perpetuate the cycle of free 
radical generation. Interference with iron sequestration therefore remains a 
critical component of DOX-induced cardiotoxicity (Jungswadee, 2016). 
 
The iron chelator dexrazoxane (DXZ) has been demonstrated, in both 
preclinical and clinical studies, to reduce the cardio toxic effects of DOX. DXZ 
is currently the only FDA-approved drug for prevention of DOX-induced 
cardiotoxicity (Ichikawa et al, 2014).  Dexrazoxane is permeable to enter the 
cell, where it is metabolized into its open-ring form, ADR-925. The open-ring 
structure resembles the iron chelator EDTA (ethylenediaminetetra acetic 
acid), where it can bind free iron in the cell, decreasing intracellular 
concentrations or disrupt the association of iron with DOX. Thus, preventing 
the DOX-iron complex formation and thereby decreasing superoxide 
production. Dexrazoxane’s protective effects appear in part to be that of 
protecting the cardiac mitochondria. Lebrecht and colleagues (2007) 
demonstrated that cardiomyocytes from rats treated with DOX and 
dexrazoxane for seven weeks had greater mitochondrial function than rats 
treated with DOX alone (Lebrecht et al, 2007). However in the recent years 
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the efficiency of dexrazoxane has reduced, overall it provides protection 
against cardiotoxicity but not adequate enough to supress against 
cardiotoxicity (Liesse et al, 2018). 
Exposure to DOX also induces iron accumulation specifically in mitochondria, 
and mice with heart-specific deletion of ABCB8 that is involved in iron export 
out of the mitochondria were a lot of sensitive to DOX cardiotoxicity. The 
decrease or deletion of this gene caused retention of iron in the mitochondria 
(Ichikawa et al., 2014). Thus it is likely to disrupt cardiac function by 
generating oxidative stress and impairing the mitochondrial function. 
 
1.8.2 Mechanism of action of DOX viaTopoisomerase II  
 
The oxidant role of DOX was originally thought to be singular however it has 
become evident that doxorubicin's interaction with topoisomerases is of 
primary importance (Yang et al, 2014). Topoisomerases are highly conserved 
proteins in many organisms. DNA topoisomerases are ubiquitous enzymes 
that control the topology of DNA by cutting and resealing one or two strands 
of DNA double helices, thereby allowing DNA stands or double helices to 
pass through or rotate around each other (Zhang et al, 2007). DNA 
topoisomerases monitor, modify, and maintain the proper topology of DNA 
during replication, transcription, recombination, and repair. They have also 
been implicated in apoptotic DNA degradation (Lodish et al, 1995). Human 
cells contain six topoisomerases: 2 types IA, two types IB, and 2 types IIA; 
every catalyst being coded by a unique gene. Type I topoisomerases cleave 
and religate one strand of DNA at a time, whereas type II enzymes catalyse 
the cleavage-religation of 2 strands of the DNA duplex in concert. 
Topoisomerase type IIs differ from topoisomerase type I which induce only 
single DNA strand breaks to relieve torsional stress formed during biological 
processes such as DNA replication and transcription (Corbett and Berger, 
2004; Nitiss, 2009). 
45 
 
Topoisomerase II is essential for decatenation of DNA- a process important 
for replication and transcription of DNA during mitosis, and deficiency in 
topoisomerase II prevents normal cytokinesis resulting in cell death. 
Doxorubicin has also been described as a poison of the DNA decatenating 
enzyme topoisomerase II whereby the drug stabilises the topoisomerase II-
DNA cleavable complexes (Figure 1.12). Topoisomerase II acts to cleave 
one strand of duplex DNA, allowing a second duplex strand to pass through. 
Once it has passed through, the first strand of duplex DNA is re-sealed 
(Berger et al, 1996; Swift et al, 2003; Swift et al, 2007).  
The interaction of topoisomerase II and doxorubicin has been described 
whereby the drug inserts into the minor groove of duplex DNA alongside the 
topoisomerase protein, resulting in stabilisation of the cleavable complex 
through a protein–drug interaction (Moro et al, 2004). Stabilisation of the 
cleavable complex results in the stalling of topoisomerase enzymatic activity 
and the induction of a DNA double strand breaks. This break is then thought 
to become a cytotoxic lesion, resulting in apoptosis. (Swift et al, 2008). It 
has been demonstrated by Zhang and colleagues, the cardiomyocyte 
specific deletion of topoisomerase IIβ in mice protects cardiomyocytes from 
doxorubicin-induced DNA double-strand breaks and transcriptome changes 
that are responsible for defective mitochondrial biogenesis and ROS 
formation by 70% compared to the control. In addition it blocked DOX 
induced decrease in cardiac ejection fraction and prevented the development 
of doxorubicin-induced progressive heart failure in mice, suggesting that 
doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in 





Figure 1.12: Mechanisms of Doxorubicin involved in topoisomerase IIβ 




1.8.4 Calcium homeostasis dysregulation 
 
Calcium imbalance is an important mechanism of toxicity of DOX. Precise 
temporal-spatial regulation of calcium is crucial for the correct function of the 
heart (Gopal, 2015). Doxorubicin directly exerts its effect on level of important 
component of sarcomeric reticulum calcium release or uptake channels, for 
example, ryanodine receptor (RYR2) and sarco-/endoplasmic reticulum 
Ca2+ ATPase (SERCA2).  In cardiac excitation and contraction coupling, a 
small amount of Ca2+ enters through the L-type Ca2+ channel during 
membrane depolarization. This Ca2+ influx triggers a large scale release of 
Ca2+ from the Sarcoplasmic Reticulum (SR) membrane via Ryanodine 
Receptor (RyR). Released Ca 2+ binds to myofibirillar proteins, TnC-induce 
muscle contraction (Arai et al, 1992). Intracellular Ca2+ concentrations are 
regulated by three membrane systems; a plasma membrane system, a 
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sarcoplasmic reticulum (SR) membrane system and a mitochondrial 
membrane system. 
Muscle relaxation is started by ATP-dependent Ca2+ transport into the SR by 
SERCA. The function of SERCA2 is regulated by the phosphorylated protein 
phospholamban. The majority of Ca2+ transported into the SR lumen is 
bound to the Ca2+, binding protein - calsequestrin. Other routes for Ca 2+ 
removal from the cytosol are those via the plasma membrane Ca2+-ATPase 
and the sodium-calcium exchanger (Na+/Ca2+ exchanger) on the plasma 
membrane. Ca 2+ transport through the mitochondrial membrane is thought 
to be a passive process (Gopal, 2015).  
The endoplasmic reticulum (ER) plays an important role in multiple cellular 
processes such as folding of secretory and membrane proteins, lipid 
biosynthesis and calcium homeostasis.  Various factors, such as oxidative 
stress and the disturbance of calcium compartmentalization, which interferes 
with ER function, lead to the accumulation of unfolded proteins which disrupt 
the membrane proteins (Rochette et al, 2015). Free radical generated by 
oxidative stress readily attack polyunsaturated fatty acids of the lipid 
membrane and decrease the membrane fluidity. As a result, the modifications 
of the lipid structure in the ER membrane suggest the activity of SERCA is 
inhibited (Kaplan et al, 2003), thereby disturbing the function of membrane-
bound protein including mitochondrial calcium channel. The stress caused by 
this situation to the ER results in disruption of ER calcium homeostasis and 
accumulation of calcium concentrations inside ER.  
 
Sustained increase in intracellular Ca2+ concentrations activates calcineurin. 
Calcineurin is a ubiquitously expressed serine/threonine phosphatase that 
exists as a heterodimer, comprised of a 59-kDa calcium-binding catalytic A 
subunit and a 19-kDa Ca2+-binding regulatory B subunit (Lodish et al, 1995). 
Activation of calcineurin is mediated by binding of Ca2+ and calmodulin to the 
regulatory and catalytic subunits, respectively. Calmodulin is an essential 
subunit of many plasma membrane Ca2+ ATPases. A rise in Ca2+ induces 
the binding of Ca2+ ions to calmodulin, which triggers an allosteric activation 
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of the Ca2+ ATPase as result the export of Ca2+ ions from the cell accelerates 
and the original Ca2+ is restored (Kang, 2001).  
Doxorubicin can directly affect the expression level of important component of 
sarcomeric reticulum calcium release or uptake channels, for example, 
ryanodine receptor and SERCA2, leading to an impaired calcium handling and 
subsequent impaired cardiac contraction. It has been reported that DOX 
modifies the thiol group (–SH) of RYR2. This modification enhances the 
probability of RYR2 channel to adopt its open state, making cytosol overloaded 
with calcium ions. Additionally, DOX could increase the activity of voltage-
sensitive L-type calcium channel on cardiac cell membrane as well as 
inhibiting the Na+/Ca2+ exchanger (NCX) on sarcolemmal membrane, resulting 
in calcium overload (Figure 1.13). 
 
When cytosolic calcium ions were excessive, the relaxed state after 
contraction would be undermined, and thus the contraction-relaxation cycle of 
cardiomyocytes is interrupted. DOX’s major metabolite doxorubicinol was 
shown to have more profound effect on contraction-relaxation cycle as 
compared to DOX. Doxorubicinol could inhibit RYR2, Na+/K+ pump on the cell 
membrane, and proton pump on mitochondria, resulting in the impairment of 
relaxation. 
 
Treatment with doxorubicin will increase oxidative stress and disrupts 
calcium equilibrium among the cell (Zhang et al., 2009). ROS raises calcium 
levels by promoting its release from the sarcoplasmic reticulum. This 
successively creates a vicious circle where elevated Ca2+ levels then 
increase ROS production through Ca2+-sensitive ROS-producing enzymes 
(Zhang et al., 2009). Since the mitochondria are located in close proximity to 
the Ca2+-release site, they are exposed to massive quantities of Ca2+. The 
overwhelming levels of ROS, in conjunction with elevated levels of Ca2+ 
beyond the threshold, trigger the opening of the mitochondrial permeability 
transition pore (mPTP). This causes a loss in mitochondrial membrane 
potential and ultimately the discharge of cytochrome c (Zhang et al., 2009). 
Cytochrome c, situated within the inner mitochondrial membrane, (Childs et 
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al., 2002; Chen et al., 2007) forms a part of the intrinsic apoptotic pathway. 
As a result this vicious process of calcium mishandling in the cells leads to 





Figure 1.13: The crosstalk between calcium and ROS in mitochondria and 
the endoplasmic reticulum. SERCA – sarco/endoplasmic reticulum Ca2+ 
ATPase; RyR – ryanodine receptors; IP3R – IP3 receptor; VDAC – voltage-
dependent anion channel; ANT – adenine-nucleotide transporter; mPTP – 
mitochondrial permeability transition pore; mNCX – mitochondrial 






1.8.5 Lipid Peroxidation  
 
DOX-induced generation of free radicals is likely to lead to lipid peroxidation 
of the cell membrane. When free radicals are produced close to cell 
membranes, OH- radicals attack the fatty acids within the membrane, 
generating a carbon-cantered free radical (Horenstein et al., 2000). Carbon-
cantered free radicals then react with oxygen to form peroxyl radicals which 
in turn form lipid hydro peroxides that increase membrane permeability. Lipid 
hydro peroxides can also form toxic by-products such as malondialdehyde 
(MDA) which can damage membrane proteins and render membrane-bound 
enzymes inactive (Horenstein et al., 2000). MDA is a mutagen in human and 
bacterial cells and carcinogenic in rats and causes large insertions and 
deletions of DNA at GC-rich regions (Niedernhofer et al., 2003) Studies 
assessing lipid peroxidation have been carried out under non-physiological 
conditions and at elevated concentrations of DOX, conditions which alone will 
promote oxidative stress and contribute towards cardiotoxicity (Gewirtz, 
1999).  
Glutathione (GSH) reduces harmful peroxides into less harmful alcohols in 
the presence of glutathione peroxidase-1 (GSH-Px1) and in doing so 
becomes oxidized to glutathione disulphide (GSSG). GSSG is then recycled 
back into GSH in the presence of glutathione reductase and NADPH (Olson 
et al., 1981). GSH is abundant in the cytosol, nucleus and mitochondria, 
highlighting the importance of this antioxidant within a cell (Valko et al., 
2007). GSH protects against oxidative stress by scavenging hydroxyl radicals 
and detoxifying hydrogen and lipid peroxides (Masella et al., 2005). 
Unfortunately, treatment with DOX can deplete endogenous GSH and inhibit 
GSH-Px1 function which then reduces the ability to clear out harmful 
peroxides and leads to cell dysfunction (Mukherjee et al., 2003; Siveski-





1.9 Doxorubicin regulated gene expression in heart failure progression 
 
Mitochondrial Dysfunction 
Mitochondrial morphology is important for maintenance of mitochondrial 
network and cellular physiology. Mitochondria are the primary targets of Dox 
resulting in mitochondrial dysfunction, oxidative stress and activating 
intracellular signalling pathways for apoptosis. The mitochondrial fusion and 
fission process is important for maintaining functional mitochondria. When 
cells undergo through a stress environment, the fusion process causes 
mitochondrial elongation and the fission process cause mitochondrial 
fragmentation. These events lead towards apoptosis at the end stage. 
Doxorubicin disrupts the mitochondrial fusion and fission process by altering 
the expression of genes mitofusins 1 and 2 (mfn1, mfn2) and optic atrophy 
protein 1 (OPA1) which are key regulatory genes involved in mitochondrial 
fusion and fission. Mitochondrial fission and fusion are accomplished by four 
GTPases in the dynamin family: (Mfn1) and (Mfn2) for outer mitochondrial 
membrane fusion, OPA1 for inner mitochondrial membrane fusion, and 
dynamin-related protein 1 (Drp1) for fission (Papanicolaou et al., 2012). 
Excessive or unopposed fission could lead to mitochondrial 
fragmentation, mitophagy, decreased anti-oxidative capacity and increased 
production of reactive oxygen species (ROS) and ultimately the cell death. 
OPA 1 and Mfn2 are down regulated in ischemic heart failure models, with 
OPA 1 mainly involved in mitochondrial cristae remodelling leading to 
increase fragmented mitochondria and greatly reduced oxygen consumption 
and electrochemical potential. Mfn2 down regulation greatly impairs the  
metabolic parameters of mitochondria along with the development of left 
ventricular hypertrophy observed in mouse models (Chiong et al, 2014; Tang 
et al, 2017). 
Mitochondrial uncoupling protein 2 (UCP2) is the most popular protein in its 
family of mitochondrial anion carrier proteins. Mitochondrial uncoupling 
proteins are located in the mitochondrial inner membrane which can promote 
the proton leak across the mitochondrial inner membrane. It is the essential 
regulator of mitochondrial membrane potential, that disperse the 
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mitochondria proton gradient by translocating H+ across the inner 
membrane, following with respiratory activity, ROS and ATP generation (Yu 
et al, 2000). Many studies demonstrated that UCP2 has protective effect on 
myocardial damage, and down-regulated UCP2 is associated with failing 
heart (Chen et al, 2014). It has been well established that increased ROS 
production and a marked reduction in expression of anti-oxidant enzymes are 
associated with the cardiotoxicity of Dox.  UCP 2 knockout studies show that 
down regulation of the gene causes changes in morphology, mitochondrial 
membrane potential loss, mitochondrial Ca2+ overload, the opening of 
mitochondrial permeability transition pore, and subsequent increased ROS 
generation as well as ATP reduction also apoptosis-associated proteins 





Malignant arrhythmias account for a significant portion of heart failure related 
deaths (Sadredini et al, 2016). The heart beats with remarkable fidelity and 
resilience but however under certain circumstances the heart rhythm can fail. 
This phenomenon is referred as cardiac arrhythmia. Cardiac arrhythmia 
arises in three categories such as automaticity, triggered activity and re- 
entry. Automaticity is when there is acceleration in the spontaneous firing 
rate of the myocytes generated from the sinoatrial node or elsewhere. The 
automaticity of ventricular myocytes is at normal levels but however they are 
elevated in response to a cardiac disease (Mersirca et al, 2015). Irregular 
activation patterns arise which results in wave fronts originating from 
ventricular loci collide with the wave fronts from sinoatrial node disturbing 
the normal rhythm of the heart (Zhang et al, 2015). 
The SCN5A gene is located in chromosome 3p21 with 28 exons and is a 
member of the human voltage-gated sodium channel gene family and 
encodes alpha subunit of the main cardiac sodium channel Na v 1.5. Na v 
1.5 is known to be responsible for maintaining the normal function of inward 
sodium current. This current is the main component in fast depolarization 
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phase after which the excitation–contraction coupling cascade along with 
proper conduction of the electrical impulse is subsequently initiated within the 
heart. 
Doxorubicin induced free radical formation in mitochondria and sarcoplasmic 
reticulum alters the membrane potential of the sodium gated ion channels 
and supresses the expression of the gene. Aberrant sodium channels 
resulting from lowly expression of SCN5A would potentially cause 
disorganization of the cardiac electrophysiological system, produce various 
arrhythmias and result in structural heart diseases. Inward and outward 
transmembrane currents are in dynamic balance physiologically, while 
variants in SCN5A could induce two states in the sodium channel: “gain-of- 
function state” or “loss-of-function state” (Zhang et al, 2018). 
Within the subunits of the Na v 1.5 channel there are major 4 domains DI-DIV 
(Zhao et al, 2015). In long QT syndrome this gene becomes mutated and 
leads to gain of function in the intracellular domain between DIII-DIV. As a 
result prolongation of action potentials occur which sets up a substrate for 
arrhythmias (Musa et al, 2015). In ventricular fibrillation, SCN5A has loss of 
function that reduces the sodium current flow, shortens the action potential 
duration and decelerates the conduction velocity. This creates a substrate for 
re-entrant arrhythmias (Saffitz and Corradi, 2016). 
 
Cardiac Remodelling 
Cardiac remodelling is defined as a group of molecular, cellular and 
interstitial changes that manifest clinically in changes in size, mass, geometry 
and function of the heart after injury. Cardiac remodelling encompasses the 
changes at the cellular and gene expression level that occur upon after the 
injury.  Janice Pfeffer was the first researcher to use the term remodelling in 
the current context, to describe the progressive increase of the left ventricular 
cavity in experimental model of myocardial infarction rat models. There are 
two types of cardiac remodelling which were recognized - physiological 
(adaptive) remodelling and pathological remodelling (Azevedo et al, 2016). 
Cardiomyocyte hypertrophy, a major consequence of pressure or volume 
overload, plays a central role in the progression of heart failure and lethal 
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cardiac arrhythmias. Cardiomyocytes become enlarged to increase muscle 
mass to reduce wall stress (Watkins et al, 2011). 
Intermediate effect of DOX can take place from weeks to months which can 
lead to remodelling of the heart. Myh7 gene encodes beta (β)-myosin heavy 
chain (β-MHC). In cardiac muscle cells β-MHC forms part of a large protein 
known as type II myosin and it is responsible for the interaction with actin 
protein for cell movement and shape. During cardiotoxicity the gene 
disruption causes up-regulation of β-MHC with corresponding downregulation 
of α-MHC. This happens through p38 MAPK, extracellular signal regulated 
kinase (ERK) and c-Jun NH2-terminal kinase (JNK) signalling pathways. 
Cardiac remodelling could lead to the development of hypertrophy in the 





There are several contributing factors towards heart failure which eventually 
leads to cardiac death. Doxorubicin is a potent producer of ROS during 
oxidative stress which in turn affects the calcium handling in the 
mitochondria. Calcium cycling is crucial for both contraction and relaxation in 
cardiomyocytes. Mitochondrial calcium overload has also been linked to 
increased ROS release and reduced ATP production in heart failure. 
Mitochondrial calcium is mainly involved in cardiac contraction and electron 
transport chain to maintain cellular energy homeostasis. In heart failure, this 
process is disrupted, and disturbed mitochondrial Ca 2+  uptake culminates 
in NADPH oxidation and ROS generation and accumulation. Both defective 
Ca 2+ and Na + handling was proposed to initiate a vicious cycle leading to 
changes in NAD(P)H/NAD(P) + redox state and oxidative stress, which 
potentially affects excitation contraction coupling (ECC), cardiac dysfunction 
and heart failure (Kiyuna et al, 2018). 
The process of excitation contraction coupling (ECC) in the ventricular 
myocyte begins with the entry of Ca2+ via the L-type Ca2+ current (ICa) 
(Bers, 2002). This relatively small Ca2+ influx is amplified by a larger Ca2+ 
release from the sarcoplasmic reticulum (SR). The resulting increase in 
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intracellular (cytoplasmic) Ca2+ concentration results in conformational 
changes in the myofilament proteins, which ultimately leads to cross bridge 
cycling and myocyte contraction. Cardiac sarcoplasmic reticulum Ca 2+ - 
ATPase 2a (Serca2a) is a fundamental protein involved in the process of 
removing Ca 2+ into the sarcoplasmic reticulum during diastole. SERCA2a 
transports the Ca2+ released during ECC back into the SR lumen against the 
electrochemical [Ca2+] gradient using chemical energy from ATP. However, 
in heart failure there is a reduction of Serca2a protein level and function. 
Hasenfuss and colleagues (1994) investigated the relationship between the 
SERCA2a levels in failing human myocardium. The finding showed that 
reduced SR Ca2+-ATPase protein levels in failing myocardium is consistent 
with measurements showing that expression of SR Ca2+-ATPase is reduced 
at the level of the mRNA in failing compared with non-failing human 
myocardium (Hasenfuss et al, 1994). 
 
MS1 is a myofibrillar protein involved in the regulation of gene expression in 
both cardiac and skeletal muscle. It is also known as striated muscle 
activator of Rho Signalling and Serum Response Factor dependent 
transcription (STARS) (Arai et al, 2002) or Actin-binding Rho-activating 
protein (ABRA) (Troidl et al, 2009). It was initially discovered by Mhahadeva 
and colleagues where they identified an array of genes that were differentially 
expressed; acutely up-regulated post-aortic banding in a pressure-overload 
rat model for left ventricular hypertrophy (LVH) (Mahadeva 
et al, 1998). One of these differentially expressed acutely induced cDNA 
fragments were subsequently characterised and designated ms1 (Mahadeva 










The intrinsic pathway firmly controlled by the Bcl-2 protein family including 
anti- apoptosis Bcl-2, Bcl-xL, pro- apoptosis Bax, Bak. The counter apoptotic 
controls apoptosis by restraining the pro- apoptotic factors, for example, Bax, 
cytochrome c discharge, caspase-9 and the executioner caspase-3 that 
prompt apoptosis (Radogna et al., 2007; Shamas et al., 2013). In this way, 
the proportions between the anti and pro- apoptotic Bcl-2 family 
characterizes whether apoptosis would happen or not. Dong et al., (2014) 
proposed that In H9C2 cells DOX-intervened a lessening in the expression of 
Bcl-2 and Bcl-xL actuating PARP and caspase-3 resulting in cardiomyocytes 
apoptosis. Dox induced oxidative stress and apoptosis shows a down 
regulation of Bcl-2 and an up regulation of Bax, cleaved caspase 3 and 























The overall aim of this thesis was to elucidate the protective properties of 
melatonin against drug - induced cardiac stress and explore its mechanisms 
of action in vitro. 
 
Specific experimental objectives 
 
I. To examine the beneficial effects of melatonin on the metabolic 
phenotype in cardiac cells during stress. 
 
II. To deduce the effect of melatonin in the attenuation of drug 
induced apoptosis in cardiac cells in vitro. 
 
III. To examine expression of genes, part of key cellular pathways to 
provide insight into mechanism of DOX-induced cardiotoxicity and 





























2.1 H9c2 Cell line 
 
The rat embryonic ventricular cardiomyoblast cell line, H9c2, has been 
extensively used as a cell model system in cardiac research, in particular 
stress-related pathways (e.g. Fothergill and Chong, 2014; Pisarenko et al., 
2015; Wang et al., 2015; Watkins et al., 2014). Recently, H9c2 cells have 
been utilised in cardiac metabolism analysis using the Seahorse machine 
(e.g. Cheung et al., 2015; Porter et al., 2014; Scurtu et al., 2015; Yang et al., 
2015). H9c2 cells have been demonstrated to reflect primary rat ventricular 
cardiomyocytes in diverse pathological conditions including hypertrophy, 
hypoxia-reoxygenation, IR and oxidative stress (e.g. Watkins et al., 2011; 
Kuznetsov et al., 2015). Collectively, this makes the H9c2 cells an ideal 
system to use in this project. 
H9c2 cells (16-19), were cultured as monolayers in Dulbecco's modified 
Eagle's medium supplemented with fetal calf serum (10%) and penicillin (1%) 
under an atmosphere of 5% CO2 at 37°C incubator. The medium was 
replenished every 2 days. Once the cells reach 70% of confluence, they were 
washed with 0.5% of trypsin EDTA solution for cell detachment and 
centrifuged at 20ᵒ C, 1500g for 5 minutes. H9c2 cells were then counted, 
seeded into appropriate plates and/or flasks and used in subsequent 
experiments.  
 
2.2 Cell Counting 
 
After trypsinisation and centrifugation (T75 flask), the cells were resuspended 
in 5ml of media and treated with 0.5% Trypan Blue.The number of cells were 






2.3 Seahorse XF Extracellular Analyser  
 
The XF Analyser (Seahorse Bioscience) is a powerful tool used to measure 
and interrogate the major energy-producing pathways of cells - mitochondrial 
respiration and glycolysis. Two key measurements are Oxygen Consumption 
Rate (OCR) which measures mitochondrial respiration of cells and the 
Extracellular Acidification Rate (ECAR) which measures the glycolytic activity 
of cells. These measurements allows the determination of the mitochondrial 
function and dysfunction in living cells in real time.  
The Seahorse XF Cell Energy Phenotype Test is the only single assay that 
can simultaneously report baseline and maximal mitochondrial respiration 
and glycolytic activity in live cells. The Seahorse XF Cell Energy Phenotype 
Test is a reagent kit and analysis method that allows you to rapidly determine 
the energy Phenotype of the cells, plot it on an energy map, and allows to 
easily compare, metabolic phenotypes across cell types and treatment 
conditions (Figure 2.1). The response to an induced energy demand is their 
metabolic potential, it is the measure of cells' ability to meet an energy 
demand via respiration and glycolysis. It is measured by the percentage 








Metabolic potential equations for generating 
phenotype chart: 
      Stressed OCR (%) = 
Stressed OCR
Baseline OCR
 x 100 
Stressed ECAR (%) = 
Stressed ECAR
Baseline ECAR




Figure 2.1: The relative utilization of the two energy pathways of a cell 
population is determined under both baseline (Baseline Phenotype) and 
stressed (Stressed Phenotype) conditions.  
 
 
Figure 2.2: Represents the Phenotype Assay workflow in Seahorse 




Unbuffered media composition  
Seahorse XF unbuffered media consisted of Dulbecco’s Modified Eagle’s 
Medium (CAT# 103575-100), 1mM of Pyruvate (0.5 ml; 100mM stock), 4mM 
Glutamine (1 ml; 200mM stock) and 25mM Glucose (1.25 ml; 1M stock). The 
pH was adjusted to 7.4 using 5M NaOH and 5M HCl, filter sterilised through 
a 0.2μM filter and stored at 4°C until required.  
 
 
Experimental treatment conditions 
The drugs used in this experiment were melatonin (CAT#M5250) and 
doxorubicin (CAT# D1515), purchased from Sigma –Aldrich. Four 
experimental treatment conditions were used for this assay for over 24hrs. 
Group A: Untreated with no drugs (control) for 24 hrs 
Group B: Doxorubicin (0.1µM) for 24hrs 
Group C: Melatonin + Doxorubicin, pre-incubation with melatonin (1µM) for 
2hrs, thereafter addition of doxorubicin (0.1µM) for 24hrs. 
Group D: Melatonin (1µM) for 24hr 
 
 
2.3.1 Two-step seeding process for the Seahorse assay 
 
H9c2 cells were seeded in a two-step seeding process in XF24 cell culture 
plates (CAT# 100777-004), to ensure a consistent and even monolayer. Cells 
were resuspended to obtain a final seeding density in 100μl of growth media 
per well. Background correction wells were left unseeded (A1, B4, C3 and 
D6) and only 100μl media was placed into these cells (Figure 2.2). After 2 
hours in a 37°C incubator, cells were adhered and a further 150μl media was 
added to each well (including background correction wells), bringing the total 
volume in each well to 250μl. The cells were incubated overnight for 24 hours 




                
Figure 2.3: Layout of the Seahorse 24 well plate. The crossed out wells 
indicate blank wells (media only with no cells). 
 
 
2.3.2 Preparation of the Sensor Cartridge for the XF24 assay  
 
To hydrate the XF24 sensor cartridge, 1 ml of Seahorse Bioscience XF24 
Calibrant pH 7.4 media was added to each well of the utility Seahorse 
Bioscience 24-well plate. The sensor cartridge was placed back on top of the 
utility plate and stored at 37°C without CO2 overnight to prevent evaporation 
of the XF Calibrant solution. 
 
Cell plate preparation with unbuffered media  
 
The cell plate was removed from the incubator and checked for an even 
confluent monolayer. Seahorse XF media was warmed in a 37°C water bath 
and the cells were rinsed twice with 500μl of Seahorse XF media and 
replenished with 500μl of media. The cell plate was incubated at 37°C 
without CO2 for 30 minutes. 
 
Loading the XF Sensor cartridge with stressor compounds 
The stressor compounds Oligomycin and carbonyl cyanide p-
[trifluoromethoxy]-phenyl-hydrazone (FCCP) were obtained from the 
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Phenotype Kit (CAT# 103275-100). Oligomycin was suspended in 630µl of 
assay medium and FCCP was suspended in 720µl of assay medium to make 
the final concentration of each compound to 100μM. Thereafter 300µl of 
Oligomycin stock was combined with 600µl of FCCP (2µM) and 2100µl of 
assay medium to prepare a 10x stock solution. The port A of the hydrated 
sensor cartridge plate was added with 56 µl of the stock solution.  
 
2.3.3 Calibrating the sensors and running a Seahorse experiment  
 
The XF24 machine was switched ON and the instrument was stabilised to 
37°C (2 hours) before the samples were measured. An experimental 
template was designed for each experiment using the assay wizard and the 
template loaded prior to running the experiment. Once the XF sensor 
cartridge had reached the required temperature, the assay was initiated and 
the plate was loaded into the machine in the correct orientation for 
calibration. At the end of the pre-programmed calibration procedure (30 
minutes), the utility plate was replaced with the experimental cell plate and 
the assay was started. The mix/wait/measure cycle used for these 
experiments was 3 min /2 min /3 min. When the run was completed, the data 
was transferred onto Seahorse XF Cell Energy Phenotype Test Report 
Generator software analyser. The software utilises the data to calculate to 
produce values for OCR and ECAR at different time points with the addition 
of stressor compounds. The software generates line graph for both OCR and 
ECAR against time and used to generate bar charts along with the 









2.4 Flow - cytometric detection of apoptosis 
 
The annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) 
apoptosis detection kit (ab14085, Abcam) was used to detect apoptosis. 
Annexin V is a protein, vascular anticoagulant α; bound to phospholipid 
bilayers in a calcium dependent manner (Andree et al, 1990).  
Phospholipids of the cell membrane are asymmetrically distributed between 
the inner and outer leaflets of the membrane. Phosphatidylcholine and 
sphingomyelin are exposed on the external leaflet of the lipid bilayer, while 
phosphatidylserine is located on the inner surface. During apoptosis, this 
asymmetry is disrupted and phosphatidylserine becomes exposed on the 
outside surface of the plasma membrane. Propidium iodide is used together 
with annexin V-FITC, to differentiate dead cells from dying cells. Binding of 
annexin V correlated with other changes is consistent with apoptosis, 
including changes in nuclear morphology, DNA fragmentation and membrane 
leaflet symmetry. Only cells stained with both annexin V and propidium iodide 
demonstrated chromatin condensation, a late indicator of apoptosis. 
 
2.4.1 Seeding process for flow - cytometry 
 
H9c2 cells were seeded in six well culture plates, to ensure a consistent and 
even monolayer (near confluent). Cells were resuspended to obtain a final 
seeding density in 1ml of complete DMEM media per well. Thereafter, further 
1ml of complete media only was added to each well, bringing the total 
volume in each well to 2ml. The cells were incubated overnight for 24 hours 
in a 37°C humidified incubator with 5% (v/v) CO2. Thereafter the complete 
media was removed from each well and 2ml of 1% serum media was added 
into each well. The cells were incubated a further 24 hours in a 37°C 




2.4.2 Preparation of the compensation controls 
 
Compensation is required for a flow cytometry experiment because of the 
physics of fluorescence and these controls are used to differentiate the FITC 
and PI stain used in the assay.  A fluorochrome is excited and emits a photon 
in a range of wavelengths in the emission spectrum. Some of those photons 
spill into a second detector, causing single stained samples to appear double 
positive for both stains. Therefore, an application of mathematical correction 
to the data addresses this spill over. This is known as compensation. 
The cells were treated with 0.8µM doxorubicin to induce apoptosis of 
approximately 50%. The flow cytometry contains three compensation 
controls with induced apoptosis: 
 Apoptosis induced unstained ( contains no stain) control 
 Apoptosis induced PI stain only 
 Apoptosis induced Annexin V-FITC stain only 
The remaining wells were used for experimental treatments. The cells were 




2.4.3 Staining and processing of samples for apoptosis experiments 
 
H9c2 cells were washed once with 1ml of phosphate- buffered saline and 
thereafter trypsinised with 0.5ml of Trypsin-EDTA. The cells were 
resuspended twice in trypsin and thereafter the cells were transferred into 
labelled Eppendorf tubes containing 1ml of complete media [Dulbecco's 
modified Eagle's medium supplemented with foetal calf serum (10%) and 
penicillin (1%)].  
Cell count was performed to give the desired concentration of cells between 
1-5x105/ml for each different treatment groups. Final volume of 700 µl of cell 
suspension (containing 1-5x105/ml) from each treatment group was 
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transferred into labelled Eppendorf tubes and centrifuged at 1000 rcf for 5 
minutes at room temperature. 
The supernatant was discarded and the cells were resuspended in 500 µl of 
1× binding buffer containing (in mM) 10 HEPES/NaOH (pH 7.4), 140 NaCl, 
and 2.5 CaCl2. Thereafter 5µl of Annexin V-FITC was combined with 5µl of 
propidium iodide and added into the relevant Eppendorf tubes. The cells 
were washed twice in binding buffer and transferred onto labelled LP4 tubes. 
The mixture was incubated for 5 min at room temperature in the dark and 
then analysed for the percentages of early (Annexin V-FITC positive and 
propidium iodide negative) and late (annexin V-FITC positive and propidium 
iodide positive) apoptotic cells using a Cyan ADP DakoCytomation flow 
cytometer. 
 
2.4.4 Flow cytometry operation 
 
The Summit 4.4 software and flow cytometry machine were switched ON and 
the instrument stabilized to 37°C at least 30 minutes before an experiment 
was run. The appropriate lasers were turned ON at 488nm and 635nm to 
warm up and stabilise to measure fluorescent emissions of FITC and PI. An 
experimental template was designed for the experiment using the Annexin-
FITC/PI protocol assay and the template loaded prior to running the 
experiment. Once the assay was set up a sample clean calibration was 
carried out using cleaning solution, 5% bleach followed by deionized water 
and thereafter the assay was started. Once the run was completed the data 
is transferred onto Flowing software analyser to evaluate the results. The 
data is spread across four quadrants – live cells, early apoptosis, late 
apoptosis and necrosis. Cells undergoing through each different stage of 
apoptosis will be represented in the respective quadrants as percentages. 




2.5. Alamar Blue cell viability assay 
 
Alamar blue cell viability reagent is a resazurin based reagent. Resazurin is 
the active component in alarmar blue cell viability reagent is a nontoxic, cell-
permeable compound that is blue in colour and non- flouroscent. Upon 
entering live cells, the cellular reducing environment reduces resazurin to 
resorufin a compound that is red and highly fluorescent (Figure 2.3). Viable 
cells continuously convert resazurin to resorufin increasing the overall 
fluorescence and colour of the media surrounding the cells. Also, the 
conversion of resazurin to resorufin results in a pronounced colour change, 
therefore cell viability can be detected using absorbance-based plate 
readers. Therefore this makes it an established and a reliable indicator of cell 
viability and death. Alamar Blue was used in this experiment to determine cell 
viability after 24 hr treatment with doxorubicin and melatonin. 
 
 
Figure 2.4: Chemical reaction taking place when resazurin is reduced to 
resorufin (APB Biosciences, 2018).  
 
 
2.5.1 Seeding Process for Alamar stain experiments 
 
The H9c2 cells were seeded on 96 well plate to ensure a consistent 
monolayer of cells were achieved. Each well contained 100µl of complete 
DMEM media. The cells were incubated in a 37°C humidified incubator with 
5% (v/v) CO2. The day prior to the treatment the media was removed from 
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each well and replaced with 100 µl of 1% serum media. The cells were 
incubated overnight for 24hrs in a 37°C humidified incubator with 5% (v/v) 
CO2 
 
2.5.2 Treatment Conditions for flow cytometry and Alamar staining 
experiments 
 
The drugs used in this experiment were melatonin (CAT# M5250) and 
doxorubicin (CAT# D1515; Sigma). Four experimental treatment conditions 
were used for this assay for over 24hrs. 
Group A: Untreated with no drugs (control) for 24 hrs 
Group B: Doxorubicin (0.5µM) for 24hrs 
Group C: Melatonin + Doxorubicin, pre-incubation with melatonin (1µM) for 
4hrs, thereafter addition of doxorubicin (0.5µM) for 24hrs. 
Group D: Melatonin (1µM) for 24hr 
 
 
2.5.3 Determination of cell viability in Alamar staining experiments 
 
After 24 hr incubation the complete media was removed from the cells and 
replaced with 100µl of the prepared Alamar blue reagent (10µl of Alamar 
Blue+ 90µl of complete media) into each of the treated wells. In addition, two 
blank wells (no cells) contained 100µl of Alamar blue reagent were used as 
negative controls. The plate was covered with foil to protect from direct light 
and incubated in 37°C humidified incubator with 5% (v/v) CO2 for 2 hours, till 
colour change was detected. Thereafter the absorbance measurements of 
the media were recorded at 570nm and 600nm using SPECTROstar Nano 
plate reader, for the respective treatment groups. 
The following equation formula was used to determine the percentage 
reduction of Alamar blue for each different treatment groups. Thereafter, the 
data value for % reduction of Alamar blue reagent for each different 
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treatment group was expressed as relative abundance from the total 




% Reduction of Alamar blue reagent = (Eoxi600 x A570) – (Eoxi570 x A600)                   
x100                                                      (Ered570 x C600) – (Ered600 xC570) 
                                                               
 
Eoxi570 = Molar extinction coefficient (E) of oxidized Alamar blue reagent  
                at 570nm= 80586 
Eoxi600 = Molar extinction coefficient (E) of oxidized Alamar blue reagent  
                at 600nm= 117216 
Ered570 = Molar extinction coefficient (E) of reduced Alamar blue reagent  
                at 570nm= 155677 
Ered600 = Molar extinction coefficient (E) of reduced Alamar blue reagent  
                at 600nm= 14652 
A570 = absorbance of treated wells at 570nm 
A600 = absorbance of treated wells at 600nm 
C570 = absorbance of negative control wells at 570nm 





2.6. Gene expression analysis using reverse transcription-polymerase 
chain reaction (RT-PCR) 
 
2.6.1 Seeding process for gene expression analysis 
 
For each experiment, H9c2 cells were seeded at approximately 50% 
confluence in two six well plates and left overnight in a 37 C humidified 
incubator with 5% CO2. Thereafter, the cells were serum-starved (1% FCS) 
for an additional 24 hours. 
 
2.6.2 Preparation of treatment conditions for gene expression analysis 
 
Four experimental treatment conditions were used for these studies (Figure 
2.4). 
Group A: Untreated with no drugs (control) for 24 hrs 
Group B: Doxorubicin (0.5µM) for 24hrs 
Group C: Melatonin + Doxorubicin, pre-incubation with melatonin (1µM) for 
4hrs, thereafter addition of doxorubicin (0.5µM) for 24hrs. 



















2.6.3 Total RNA Extraction from H9c2 cells 
 
Following each experiment, 500μl of Trizol (CAT# 15596018; Thermo Fisher 
Scientific) were added to the cells for 5 mins to lyse the cells and thereafter 
the cells were scraped off from the well surface and transferred into labelled 
Eppendorf tubes. Next, 100μl of chloroform was added to each tube and 
vortexed for 10 seconds. Samples were left for 3mins at room temperature 
and then centrifuged at 12000 rpm for 15 mins. 
The aqueous phase (top layer) was carefully removed and transferred into a 
fresh set of labelled Eppendorf tubes and 250μl of isopropyl alcohol was 
added to each tube and samples were vortexed for few seconds. The 
samples were then placed in a -80°C freezer overnight. Thereafter, the 
samples were centrifuged at 12000 rpm for 30 mins. The supernatant was 
then completely removed and the RNA pellet was resuspended gently in 1ml 
of 70% ethanol followed by centrifugation at 7500 rpm for 5 mins. The 
supernatant was discarded and the RNA pellet was air dried for 
approximately 5-10 min. The RNA was then resuspended in 20 µL of DEPC-
treated water and incubated in a hot block (55-60°C) for 10min to solubilise 
the RNA.  The RNA yields from the samples were quantified by absorbance 
using the NanoDrop™ spectrophotometer from Thermo scientific (#ND-
2000C). The concentration of RNA was recorded and used for dilution 














2.6.4 Reverse Transcription (RT) reactions 
 
Complementary DNA (cDNA) was synthesised using the H Minus First 
Strand cDNA Synthesis Kit (CAT# K1631; Thermo Scientific), using the 
manufacturer’s instructions. RNA was extracted from the cells using H Minus 
First Strand cDNA Synthesis Kit provided by Thermo Scientific, using the 
manufacturer’s instructions. The volume of cDNA in each tube was diluted 
accordingly with RNAse free water with 11µl with the addition of 1µl oligo dT 
primer, bringing the final volume up to 12µl (Appendix A). 
Next step involved the preparation of master mix for the RT reactions. 
 
Master Mix Total=8uL 
10mM dNTP mix 2uL 
5X Reaction buffer 4uL 
Ribolock RNase Inhibitor 1uL 
Revert Aid RT 1uL 
 
 
RNA samples were denatured (65°C, 5 mins) and then kept on ice. Thereafter 
8μl of Master Mix were added to each tube to bring up the final volume to 20µl. 
The mixtures will then be incubated in a PCR machine at 42°C for 1h followed 
by 70°C for 5mins. Finally, 80µL of RNase-free water were added to each RT 








2.6.5 Semi-quantitative polymerase chain reaction (PCR) 
 
The first step involved preparation of master mix (Table 1) and labelling13 










1 Untreated 2 18 
2 Untreated 2 18 
3 Untreated 2 18 
4 Dox+Mel 2 18 
5 Dox+Mel 2 18 
6 Dox+Mel 2 18 
7 Dox alone 2 18 
8 Dox alone 2 18 
9 Dox alone 2 18 
10 Mel alone 2 18 
11 Mel alone 2 18 
12 Mel alone 2 18 








2x Taq mix 150uL 
Water  90uL 
Primer F+R 30uL 
 
 
The PCR tubes were placed in the machine under the set parameters  (Table 










Table 2. PCR parameter 
 
Initial denaturation (95C) = 2mins (only for 1 cycle) 
Denaturation (95C) = 15sec 
Annealing (58C) = 15sec 
Extension (72C) = 10sec 
Cycle number between 22-35 




2.6.6 Agarose Gel Electrophoresis 
 
 
Agarose gels (1.5%) were prepared using 1.5g agarose (#10688973, Fisher 
Bioscience) with 100ml of 1xTBE (#10130740, Fisher Bioscience) buffer and 
4μl of Gel-red (with 1-to-1 dilution with water) (#BT41003, Cambridge 
Bioscience). Molten agarose was poured into a casting tray and was left to 
set. Once set, the samples were loaded onto the gel with the 100bp 
molecular weight ladder (#N0467S, New England BioLabs). TBE buffer was 
poured on top of it until the Gel was covered with very narrow layer of TBE 
and the samples electrophoresed at 100V for 30 mins. Thereafter the gel 





2.6.7 Quantification of PCR using the Image J software 
 
Image J software was used to quantify the PCR fragments of the gel image 
for the genes. The colour of the gel image was first inverted (PCR fragments 
are black in a white background) and then each PCR fragment was selected 
and analysed. The arbitrary numerical value for each PCR fragment was 
calculated and then the percentage of each peak on the plot was calculated. 
This gave an arbitrary value for each gene from separate experiments. The 
expression levels of each experimental sample (per gene) were divided by 
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expression levels of the internal control gene (Cyclophillin A) and these ratios 
plotted and analysed. 
 
2.6.8 Primer design 
 
Primer pairs for each gene were designed using the online software 
Primer3Plus (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Coding 
regions for primer design for each gene was preselected using ENSEMBL to 
identify exonic regions with large (>1500bp) introns. These cDNA sequences 
were then copy and pasted into the Primer3Plus software. The primers were 
then selected according to the following criteria; length between 19 to 21 
base pairs, length of amplification product between 150 to 210bp, Tm of 
about 65°- 75°C, minimum of 40% and maximum of 60% GC content for 
temperature stability and sufficient strength of the bond between the primer 
and mRNA. The primers were synthesised by Fisher Bioscience. In order to 
determine the specificity of the primers, all sequences (Table 3) were 
compared with the GenBank, using the program Blast which is available at 













Table 3. Primers sequences 
Gene Forward Primer Reverse Primer Size 
(bp) 
Cycle 
Cyclo A 5'-CCACCGTGTTCTTCGACATC-3' 5'-CTGGGAACCATTTGTGTTTG-3' 150 22 






Drp1 5’-CCCAAGGATATTGAGCTTC-3’ 5’-CAGCTAGAGTTCTGCGCC-3’ 166 28 






Parp 1 5’-GTACTGGGGATGTCACTG-3’ 5’-GAGGTGATCGAGACGGGAG-3’ 192 30 
Parp 2 5’-CCAAGGTCGGAAAGGCTC-3’ 5’-CCAGAACAAGCCACCAAG-3’ 205 30 











Ucp2 5'-GCGCCAGATGAGCTTTGC-3' 5'-CCTGGAAGCGGACCTTTAC- 3' 176 28 
Ms1 5’-
GTGACAGCATAGACACAGAGGAC-3’ 
5’-CACTGCTGCCACCTGCCTT-3’ 200 30 
Serca2a 5’-CTTTCGTTTTGGCTTGGTTC-3’ 5’-ATCCGCTGCACACTCTTTCT-3’ 208 28 
Scn5a 5’-GACCCATTTGCCGACCTCAC-3’ 5’-GTAGTAGGGGTCAAGGGCG-3’ 180 28 











2.7. Quantitative real-time PCR 
 
2.7.1 Preparation of the PCR reaction 
 
Quantitative real-time PCR was performed using PowerUp SYBR Green 
(CAT#A25742) purchased from Thermo Fisher Scientific. Multiple reactions 
were performed using the master mix. Typical 10µl reaction contained the 
following: 
Component Total=10uL 
PowerUp SYBR green 
master mix 
5uL 
Forward and Reverse primer 1uL 
cDNA (1µg) 1uL 
Nuclease free water 3uL 
 
The reaction mixture (10uL) was pipetted into each well of an Optical 96- well 
reaction plate (CAT#4346907). The plate was sealed and centrifuged briefly 















2.7.2 Quantitative real-time PCR 
 
Polymerase chain reaction (PCR) was conducted on a 7500 Fast Real‐Time 
PCR System (Applied Biosystems). Cyclophilin A and 36B4 were used as 
internal controls for standardisation.  
Once the Optical 96- well reaction plate was placed in the instrument the 
following thermal cycling conditions were used for this amplification reaction. 
 
Initial Holding Stage 50°C 2 minutes 
Holding Stage 95°C 2 minutes 
Denaturation Stage 
(40 cycles) 
95°C 3 seconds 
Annealing and 
Extension Stage 






















2.7.3 Data analysis and quantification of quantitative PCR 
 
The threshold cycle (REF) values were obtained from the amplification curve 
using the comparative ΔΔCT method. This method allows the quantitative 
determination of fold induction of gene of interest between different samples 
using the following formula; 
Fold induction = 2-ΔΔCT 
ΔCT = mean CT (gene of interest) - mean CT (reference gene) 
ΔΔCT = ΔCT (unknown) - ΔCT (control) 
The control sample, which is represented by the non-treated allows for 
corrections to be made for inter-assay variation. It is important to note that 
the above formula is based on the assumption that the efficient of the PCR 
reaction for both the reference internal control gene, and the gene of interest 
is identical with a doubling of product being achieved with every cycle 
 
 
2.6. Statistical analysis 
 
Data are presented as mean ± SEM. Group data were analysed using One -
way ANOVA with multiple comparisons and post-hoc Tukey corrections. The 
analyses were performed using GraphPad Prism 7.0 software. P values of 





























Mitochondria are the primary organelle for physiological reactive oxygen 
species (ROS) production and is also the main target for damage caused by 
chronic sustained over production of ROS. Chronic pathological ROS 
production is extremely detrimental for cardiomyocytes (Ghao et al, 2012). 
This overload of free radicals includes hydroxyl radicals (∙OH), superoxide 
(O2 ∙−), hydrogen peroxide (H2O2), nitric oxide (NO), and peroxynitrite 
(OONO-). These free radicals promote macromolecule damage such as 
DNA, lipids, proteins, and carbohydrates oxidation (Lee and Won, 2014; 
Lopez et al, 2017; Capetta et al, 2017). This production of ROS can act as 
intracellular signalling molecule for various destructive pathways which 
include apoptotic pathway. Once activated, it leads to release of apoptotic 
factors such as cytochrome c and apoptosis-inducing factor (AIF), ultimately 
leading to cardiac cell death (Niizuma et al, 2010). Hydrogen peroxide and 
Isoproterenol are potent inducers of ischemia and hypertrophy in cardiac 
cells. They trigger the production of ROS in mitochondria leading to 
mitochondrial metabolic dysfunction and eventually loss of function. 
Hydrogen peroxide is a potent generator for reactive oxygen species. These 
ROS species are capable of generating cellular damage during myocardial 
ischemia and reperfusion. Hydrogen peroxide is the most stable and 
therefore, has the greatest potential to diffuse from its origin of production to 
cause tissue damage at distant sites. Several studies have examined the 
myocardial effects of hydrogen peroxide. It was observed that H2O2 can 
induce arrhythmias, reduce myocardial function, lipid peroxidation, enzyme 
activation and as well as altering intracellular calcium concentrations. 
Hydrogen peroxide can activate enzymes by oxidation in the downstream 
signalling pathway of PKC (Kumaran and Mainzen, 2010). The specific 
activation of PKC pathway mediates deleterious effects of myocardial 
ischemia and reperfusion injury. Within the narrow window of exposure to 
H2O2, the PKC dependence causes changes in the intracellular calcium ion 
concentrations and cell shortening of the ventricular myocytes (Nizuma et al, 
2010).   
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Isoproterenol (ISO) is a manufactured catecholamine with the expansion of 
two methyl groups. It is structurally similar to adrenaline and mimics the 
sustained adrenergic receptor activation which represents an important 
hallmark of the pathogenesis of maladaptive cardiac hypertrophy (Lalitha et 
al, 2013). The activation of β-adrenergic signalling in turn induces many 
different pathological mechanisms which contribute to the hypertrophic 
phenotype including enhanced protein synthesis, proto-oncogene 
expression, elevated oxidative stress, stimulation of mitogen activated protein 
kinases and phosphotidyl inositol-3 kinases (Turrubiarte et al, 2015). A single 
high subcutaneous (SC) dose of ISO between 10 and 85 mg/kg in adult rats 
causes myocardial necrosis and fibrosis (Heather et al, 2009; Roy and 
Mainzen, 2013). Low doses of ISO (0.3 to 6 mg/kg) during the 1st, 2nd and 
3rd weeks induce necrosis in areas of the myocardium (Ribeiro et al, 2009). 
In turn, moderate doses (35 mg/kg) administered SC for 3 days induced 
dilated cardiomyopathy. Chronic treatment (100 mg/kg) > 2 weeks in adult 
rats produces diastolic dysfunction and causes decrease of fatty acids and 
glucose in the myocardium (Turrubiarte et al, 2015). 
To investigate the effects of oxidative stress induced by hydrogen peroxide 
and isoproterenol in H9c2 cells, the Seahorse XF Analyser (Seahorse 
Bioscience) is used. It is a powerful tool used to measure and interrogate the 
major energy-producing pathways of cells - mitochondrial respiration and 
glycolysis. Two key measurements are Oxygen Consumption Rate (OCR) 
which measures mitochondrial respiration of cells and the Extracellular 
Acidification Rate (ECAR) which measures the glycolytic activity of cells. 
These measurements allow the determination of the mitochondrial function 
and dysfunction in living cells in real time.   
 
Aims 
The studies outlined in this chapter will examine the effect of simulated 
oxidative stress induced by hydrogen peroxide and Isoproterenol on 
mitochondrial metabolism and dysfunction in H9c2 cells in vitro. The 





3.2.1 Seeding Density 
 
Seeding densities of 6000, 12,000, 25,000 and 40,000 of H9c2 cells were 
experimented to determine the optimum seeding density for the growth of 





Figure 3.1:  OCR induction for different seeding density of H9c2 cells. 
H9c2 cells were seeded at different densities of 6k, 12k, 25k and 40k per well 
in Seahorse Bioscience culture plates for 24 hrs. Initially the baseline 
measurements of Oxygen consumption rate (OCR) were made. 
Oligomycin/FCCP mix (1μM/2μM) was injected to determine the maximum 
oxygen consumption in these cells. The experiment was repeated and 
produced similar results. Data shown are mean± SEM, n=6 per group. One 




The results indicate a seeding density of approximately 40,000 cells where 
there is a good FCCP induction in the cells and the baseline OCR 
measurement lie within the range (100-200 pmol/min) (Seahorse Bioscience, 
2016). At 6k and 12k, the cells have not reached a consistent monolayer, 
indicated by the low OCR values. At 25k the cells produced OCR induction at 
baseline of 100 pmol/min, however it was low compared to the OCR 
induction given by cells seeded at 40,000. At 40k the cells produced a good 
response towards FCCP and gave a consistent OCR induction. 
 
 
3.2.2 FCCP Optimisation 
 
The optimisation of FCCP was determined on H9c2 cells pre-treated with 









Figure 3.2: FCCP dose response (optimisation) for H9c2 cells pre-
treated with H2O2. H9c2 cells were seeded at 40k and treated with H2O2 
(200µM) for 24hrs. The initial OCR measurements were made. Then different 
concentrations of FCCP (0.1 µM, 0.5 µM and 1 µM) were injected to 
determine maximum OCR of the cells. The experiment was repeated and 
produced similar results.  Data shown is mean± SEM, n=6 per group. One 
Way Anova: F (2, 21) = 21.12, *P<0.0001. 
* * * * 
* 























In the current study, the optimum FCCP concentration used on H9c2 cells 
was 1μM (Figure 3.2). FCCP at 1 μM provided consistent induction with the 
maximum OCR for these experiments (Figure 3.3).  
 
 
Figure 3.3: Maximum OCR in H9c2 cells induced by mitochondrial stressors 
(oligomycin and FCCP). The induction was 2.3±0.2 fold [n=12 separate 
experiments (6-7 wells per experiment), ****p<0.0001]. The experiment was 
repeated and produced similar results. 
 
 
3.2.3 The effect of hydrogen peroxide on metabolic phenotype in H9c2    
cells 
 
The effect of melatonin alone on mitochondrial function was examined using 
the Seahorse assay and this showed no change in oxygen consumption rate 
(Figure 3.4). 
Hydrogen peroxide (H2O2) is a stress inducer in H9c2 cardiomyocytes by 
generating oxidative stress and inducing cellular hypertrophy in vitro 
(Petrosillo et al, 2010). 


























Figure 3.4. Effect of melatonin alone on oxygen consumption rate 
(OCR). Control (untreated) had no drugs. Melatonin (1µM) was used for 
24hrs.  Melatonin had no effect on OCR when compared with the control. 
The experiment was repeated 5 times and produced similar results. Data 















Figure 3.5: Hydrogen peroxide decreases maximum OCR in 




(200uM and 400uM) for 24hrs. The FCCP concentration of 1uM 
was injected to determine the maximum OCR. (A) OCR changes 




(B) Peak OCR changes during 










towards energetic. The experiment was repeated and produced 
similar results. Data shown is mean± SEM, n=6 per group. One 






Hydrogen peroxide treatment decreased maximum OCR by ~45% (Figure 
3.5A & B) at both 200 and 400 µM. The phenotype chart indicates the 
metabolic phenotype of the cells. Hydrogen peroxide decreased the 
energetic of the cells and lowered glycolysis capacity (Figure 3.5C).  
In order to test the beneficial effect of melatonin, H9c2 cells were pre-treated 
with melatonin and then treated with hydrogen peroxide (200 µM) for 24 hrs. 
Pre-treatment of H9c2 cells with melatonin blocked the decrease in maximum 














Figure 3.6: Melatonin attenuated hydrogen peroxide 
reduction of maximum OCR in H9c2 cells. The cells are pre- 
treated with 200µM of H2O2 with pre-incubation of melatonin 
(1µM), for 24hrs. (A) OCR changes with 200µM H2O2 and 
melatonin. (B) Peak OCR changes during baseline and 
stressed conditions. (C) Cell energetic changes for 200µm 
H2O2 and melatonin. The experiment was repeated and 
produced similar results. Data shown is mean± SEM, n=6 per 






3.2.4 Isoproterenol decreased maximum oxygen consumption rate in 
H9c2 cells 
 
Isoproterenol (ISO) treatment induces oxidative stress in H9c2 cells and 
initiate cellular hypertrophy. The current study examined the effect of ISO on 
mitochondrial function in H9c2 cells. At both 10 and 50 µM, ISO decreased 
~40% in maximum OCR (Figure 3.7), with a decrease in cell energetics 
(Figure 3.8B). Interestingly, melatonin pre-treatment (1µM, 1 hr) blocked ISO 



























Figure 3.7: Isoproterenol decreased maximum OCR in H9c2 cells. The 
cells were treated with 10µM or 50µM of isoproterenol for 24hrs. (A) OCR 
changes for 10µM and 50µM of isoproterenol. (B) Peak OCR changes during 
baseline and stressed conditions. The experiment was repeated and 
produced similar results. Data shown is mean± SEM, n=6 per group. One 






















Figure 3.8: Melatonin attenuates Isoproterenol reduction of 
maximum OCR in H9c2 cells. The cells were treated with 10µM 
isoproterenol (ISO) with melatonin (1µM) pre-incubation for 24hrs. 
(A) OCR changes in cells treated with isoproterenol and melatonin. 
(B) Peak OCR changes during baseline and stressed conditions. (C) 
Phenotype chart shows the shift towards aerobic in the three groups. 
The experiment was repeated and produced similar results. Data 
shown is mean± SEM, n=6 per group. One Way Anova: F (2, 21) = 








Cardiac disease such as heart failure and cardiac arrhythmias are complex 
disorders with multifactorial aetiology that are largely unresolved, however 
one common trigger in cardiac disease states is chronic oxidative stress. In 
the current study, the effect of well-established triggers of cardiac 
phenotypes (hydrogen peroxide and isoproterenol) were used to test if these 
compounds can alter the metabolic profile in a model cell line and examine if 
melatonin can attenuate this alteration in cardiac function in vitro. 
The main important findings of this study were: 
1. Both hydrogen peroxide and isoproterenol, at a dose that causes 
cardiac dysfunction and hypertrophy in vitro, decreased the basal and 
peak OCR in cardiac cells. 
2. A low pharmacological dose of melatonin, typically used in in vitro 
studies, attenuated or even blocked the decrease in OCR in stressed-
induced cardiac cells. 
 
In this study, H9c2 cells were under stress caused by hydrogen peroxide and 
isoproterenol. Both chemical agents are potent stress inducers in 
cardiomyocytes (Ojha, 2010) and mimic ischemic conditions in cells by 
inducing oxidative stress. In H9c2 cells oxidative stress affects mitochondria 
and functionality (Wu and Cederbaum, 2013; Shin et al, 2016; Dai et al, 
2018).  
Mitochondria are considered the main intracellular source of ROS production 
and paradoxically, the major target of a free radical attack. During normal 
physiological conditions, ROS are generated at very low levels, but can 
increase dramatically in pathophysiological conditions such as myocardial 
ischaemia/reperfusion (I/R) injury and inflammation (Paradies et al, 2010). 
These pathological changes can lead to a loss in the phospholipid cardiolipin, 
which in turn, is responsible for the loss of activity of the respiratory chain 
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complexes I, III and IV and mitochondrial dysfunction (Paradies et al, 1999; 
Lochner et al, 2015).  
Melatonin has beneficial effects in a number of pathophysiological conditions 
associated with increased oxidative stress such as hypertension, myocardial 
hypertrophy and I/R. Melatonin can exert its cardio protective actions via its 
free radical scavenging activities as well as the induction of anti-oxidant 
enzymes (Hardeland, 2005; Cardinali et al, 2006). Interestingly, Petrosillo 
and co-workers (2003) demonstrated that, at pharmacological concentrations 
(50µM), melatonin effectively protects against I/R damage: it caused a 
reduction in lipid peroxidation and counteracted the reduction in State 3 
respiration and the respiratory control ratio in rat heart mitochondria, isolated 
after exposure of the heart to I/R. This study showed that the protection by 
melatonin against mitochondrial dysfunction was associated with 
improvement in functional recovery during reperfusion (Petrosillo et al, 2003). 
One mechanism of action of melatonin in cardioprotection against I/R 
induced damage in cardiomyocytes is by inhibiting MPTP opening in the 
mitochondria (Petrosillo et al, 2009), which will stabilise membrane potential 
and inhibit cytochrome c leakage and apoptosis.  
 
In the current study, treatment of H9c2 cells with H2O2 and ISO for 24 hrs 
mimicked the ischemic situation in H9c2 cells in vitro (Ohjia, 2010). During 
ischemia, cardiomyocytes lose their ability to respire efficiently due to the 
failing mitochondria. Treatment of cells with hydrogen peroxide for 24 hours 
stimulates large amounts of ROS production.  Ultimately this uncouples 
mitochondrial function and the complexes within the ETC chain (I, III, IV) 
leading to reduced activity (Paradies et al, 1999).  The ATP synthase 
becomes the target of the free radicals which results in decreased activity to 
carry out oxidative phosphorylation. The cells starve due to the mitochondria 
dysfunctionality to carry out aerobic respiration to meet the energy demands. 




The current Seahorse data demonstrated that treatment of H9c2 cells with 
either H2O2 (200µM) or ISO (10µM) resulted in  lower OCR values due to the 
effect of free radicals  on the mitochondria respiratory chain, which 
decreased the ability of the cells to respire efficiently (Figures 3.5 and 3.7). 
Of interest, melatonin pre-treatment blocked this decrease in OCR caused by 
oxidative stress. 
At present, the mechanism of action of melatonin is unclear. Melatonin and 
its metabolites have free radical scavenging abilities and acts as a robust 
anti-oxidant for the cells (Favero et al, 2017).  It is conceivable that this 
property of melatonin directly protected against ROS-induced damage to the 
mitochondria and the ETC function, thus improving OCR (Ahmad et al, 2016; 
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Cardiotoxicity is emerging as a critical issue drug intervention in many 
treatments in particular anti-cancer therapy. Over the decades, numerous 
studies sought to identify the intracellular targets and elucidating the 
molecular mechanisms involved in drug-induced cardiotoxicity (Minotti et al, 
2004; Bassareo et al, 2016; Li et al, 2018). Majority of studies have 
contributed to the theory that it is in fact a multifactorial process that leads to 
cardiomyocyte death as the terminal downstream event (Kalyanaraman et al, 
2002; Fukazawa et al, 2003; Minotti et al, 2004). Mitochondrial dysfunction 
has become an apparent hallmark of drug-induced cardiotoxicity (Torkarska 
et al, 2006).  
Abnormalities in mitochondrial functions such as defects in the respiratory 
chain/oxidative phosphorylation (OXPHOS) system, decreased adenosine tri-
phosphate (ATP) production, a switch in metabolic substrate utilisation, 
mitochondrial deoxyribonucleic acid (DNA) damage, modulation of 
mitochondrial sirtuin activity, and a vicious cycle of free radical formation 
have all been suggested as the primary causative factors in the pathogenesis 
of drug-induced cardiotoxicity (Verma et al, 2013). These defects act 
synergistically to create a bioenergetics crisis, which culminates in 
cardiomyocytes death. Melatonin is a potent antioxidant, and has been 
shown to influence mitochondrial homeostasis and function. Although 
accumulating studies support the mitochondrial protective role of melatonin, 
the exact mechanisms by which melatonin confers mitochondrial protection in 
the context of drug-induced cardiotoxicity remain to be elucidated. The 
accumulation of drugs can impose a direct threat on the mitochondria. They 
have a high affinity for cardiolipin, an integral component of the inner 
mitochondrial membrane. The binding of these drugs to cardiolipin does not 
allow for cardiolipin interaction with key respiratory complexes 




Drugs for chronic disorders such as cardiovascular diseases, diabetes, 
depression and anxiety and cancer, conveys severe adverse effects, in 
chronic use (Vigneri et al, 2009; Nguyen et al, 2012). This chapter focuses on 
evaluating some of the most commonly used drugs in diverse disorders, 
imposing cardiotoxicity. Doxorubicin, Statins, Rosiglitazone, Amitriptyline and 
Amiodarone are among the frequently used drugs to manage a variety of 
diseases which have been known to cause mitochondrial dysfunction in 
chronic use.  
Doxorubicin (DOX) is an anthracycline commonly used in cancer treatment. 
The cardiotoxicity caused by DOX could be acute (hours to days) to 
intermediate (weeks and months) and late onset (>12 months) and even 
years after treatment has finished. However, its clinical use is greatly 
restricted by the development of cardiomyopathy and clinical congestive 
failure (Liu et al, 2008).  
Statins (HMG-CoA reductase inhibitors) are a class of lipid lowering drugs 
used in treatments for hypercholesterolemia and reduce cardiovascular 
diseases. Statins competitively inhibit the conversion of HMG-CoA to 
mevalonate, a precursor for cholesterol synthesis (Herninger and Fritz, 2017) 
thereby eventually reducing the cell’s intrinsic cholesterol synthesis and 
favouring the uptake of serum LDL cholesterol. On the other hand, statins are 
known to promote muscle weakness during prolonged time periods. Statin 
therapy is associated with decreased myocardial function and increase risks 
of stokes (Lim et al, 2013). 
Rosiglitazone is a thiazolidinedione antidiabetic drug used in treating type 2 
diabetes mellitus. It works as an insulin sensitizer, by binding to the 
peroxisome proliferator –activated receptor in cells and making the cells 
more responsive to insulin. Its use has dramatically decreased over the years 
due to association of increased risks of heart attacks and deaths (Varga et al, 
2015; Pharaon et al 2017).  
Amitriptyline is tricyclic antidepressant used to treat mainly depressions and 
other anxiety disorders. This drug has significant adverse effects on the heart 
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as it causes disturbances in the rhythm of the heart, QT prolongation, leading 
to cardiac dysfunction (Zima et al, 2008; Arici et al, 2013). 
Amiodarone is a potent antiarrhythmic agent that is used to treat ventricular 
arrhythmias and atrial fibrillation. Chronic use of amiodarone induces multiple 
organ toxicity via reduced phospholipid degradation which leads to its 
accumulation and, consequently lipid peroxidation, ROS generation, and 
disturbance of cellular calcium levels (Abuzaid et al, 2015). 
The XF Analyser (Seahorse Bioscience) is a powerful tool used to measure 
and interrogate the major energy-producing pathways of cells - mitochondrial 
respiration and glycolysis. Two key measurements are Oxygen Consumption 
Rate (OCR) which measures mitochondrial respiration of cells and the 
Extracellular Acidification Rate (ECAR) which measures the glycolytic activity 
of cells. These measurements allow the determination of the mitochondrial 
function and dysfunction in living cells in real time.  The drugs will be tested 
to evaluate mitochondrial function in H9c2 cells and the XF analyser allows to 
measure this effect. 
 
Aim 
The aim of this study is to critically evaluate mitochondrial dysfunction in 
cardiomyocytes under diverse drug treatments. The beneficial effect of 
melatonin is tested alongside these drugs to support the protective 













4.2.1 Doxorubicin treatment of H9c2 cells 
 
Doxorubicin (DOX) is an anthracycline commonly used in cancer treatment. 
The cardiotoxicity caused by DOX could be acute (hours to days) to 
intermediate (weeks and months) and late onset (>12 months) and even 
years after treatment has finished. However, its clinical use is greatly 
restricted by the development of cardiomyopathy and clinical congestive 
failure (Liu et al, 2008). It is therefore vital to understand the mitochondrial 
function of cardiomyocytes after chronic exposure to DOX-treatment. 
Measurements of OCR and ECAR thus provide excellent parameters to 
convey the toxic effects of DOX in cardiomyocytes.  
H9c2 cells were treated with two concentrations of DOX (0.1µM and 0.01µM) 
for 24 hours. The lower concentration of DOX had no significant effect on the 
OCR of H9c2 cells whereas the higher concentration (0.1µM) produced a 
consistent robust decrease in peak OCR (~40%; Figure 4.1 & 4.2). This 
concentration (0.1µM or 100 nM) was used in subsequent studies. Of 
interest, DOX-treatment decreased OCR was attenuated by melatonin. Data 
is represented as OCR values with SEM [CON, 934±30; DOX, 554±30; 
DOX+MEL, 858±30 pmol/min] (Figure 4.2). Equally important, melatonin 
































Figure 4.1: Doxorubicin decreased peak OCR in H9c2 cells. H9c2 cells 
were treated with doxorubicin (0.1µM and 0.01µM) for 24hrs. (A) OCR 
changes with 0.1µM and 0.01µM DOX. (B) Peak OCR changes during 
baseline and stressed conditions. The experiment was repeated and produced 
similar results. Data shown is mean± SEM, n=6 per group. One Way Anova: F 








Figure 4.2: Melatonin attenuates DOX-induced mitochondrial 
dysfunction in H9c2 cells. H9c2 were treated with 0.1µM DOX with 
melatonin (1µM) pre-incubation for 24hrs. (A) OCR changes in cells with 
DOX (0.1 µM) with and without MEL (1 µM). (B) Peak OCR changes 
during baseline and stressed conditions. (C) Metabolic phenotype changes 
with DOX (0.1 µM) with and without MEL (1 µM).  Data shown are mean± 







4.2.2 Statin treatment of H9c2 cells 
 
Statins (HMG-CoA reductase inhibitors) are a class of lipid lowering drugs 
used in treatments for hypercholesterolemia and reduce cardiovascular 
diseases. Statins competitively inhibit the conversion of HMG-CoA to 
mevalonate, a precursor for cholesterol synthesis (Herninger and Fritz, 
2017) thereby eventually reducing the cell’s intrinsic cholesterol synthesis 
and favouring the uptake of serum LDL cholesterol. On the other hand, 
statins are known to promote muscle weakness during prolonged time 
periods. Statin therapy is associated with decreased myocardial function and 
increase risks of stokes (Lim et al, 2013).  
Two commonly prescribed statins, Simvastatin and Pravastatin (at 
intervention concentration of 10 µM) both significantly decreased the peak 
OCR to a similar extent (~50%) (Figure 4.3). Both statins modestly 
decreased the basal OCR in H9c2 cells. The concentration of this drug was 
chosen according to previous work done on H9 c2 cells (Gan Guo et al, 
2009; Bonafacio et al, 2016). The cells were seeded at 40k and used for the 
Seahorse experiment. H9c2 cells were pre-treated with 10µM of simvastatin 
or pravastatin for 24hrs, thereafter they were treated according to the 
Seahorse experimental protocol.  
ECAR is a measure of the rate of glycolysis during mitochondrial respiration 
which was reduced by both statins (~50%) during when compared with the 
control (no statin).  Of note, Pravastatin have a slightly improved ECAR than 











* * * 
Figure 4.3: Effects of simvastatin and pravastatin on mitochondrial function in H9c2 cells. H9c2 cells were pre-treated with 10µM of simvastatin or 
pravastatin for 24hrs. (A) The OCR changes in cells treated with simvastatin and pravastatin. (B) The measure of extracellular acidification rate (ECAR) 
showing changes in glycolysis. (C) Peak OCR changes during baseline and stressed conditions. (D) The metabolic phenotypic changes in cells simvastatin and 




4.2.3 Rosiglitazone and Amitriptyline treatment 
 
Rosiglitazone is a thiazolidinedione antidiabetic drug used in treating type 2 
diabetes mellitus. It works as an insulin sensitizer, by binding to 
the peroxisome proliferator –activated receptor in cells and making the cells 
more responsive to insulin. Its use has dramatically decreased over the years 
due to association of increased risks of heart attacks and deaths (Varga et al, 
2015; Pharaon et al 2017). 
 
Amitriptyline is tricyclic antidepressant used to treat mainly depressions and 
other anxiety disorders. This drug has significant adverse effects on the heart 
as it causes disturbances in the rhythm of the heart, QT prolongation, leading 












Figure 4.4: Effects of Rosiglitazone and Amitriptyline on mitochondrial function in H9c2 cells. H9c2 cells were treated with Rosiglitazone (10µM) and 
Amitriptyline (10µM) for 24hrs.  (A) The OCR changes in cells treated with rosiglitazone and amitriptyline. (B) The measure of extracellular acidification rate 
(ECAR) showing changes in glycolysis in cells. (C) Peak OCR changes during baseline and stressed conditions. (D) The metabolic phenotypic changes in 








Rosiglitazone slightly decreased the OCR in cardiomyocytes but this was not 
significant (Figure 4.4), not even at higher concentration of 50µM (Figure 4.5) 
However, amitriptyline (at 10 µM) significantly reduced the OCR and ECAR 
(~ 20%) in H9c2 cells when compared with control (Figure 4.4).  
 
 
4.2.5 Amiodarone treatment 
 
Amiodarone is a potent antiarrhythmic agent that is used to treat ventricular 
arrhythmias and atrial fibrillation. Chronic use of amiodarone induces multiple 
organ toxicity via reduced phospholipid degradation which leads to its 
accumulation and, consequently lipid peroxidation, ROS generation, and 
disturbance of cellular calcium (Abuzaid et al, 2015). 
Unlike any other drugs that were examined in this study, amiodarone-
treatment (10µM) increased peak OCR by ~ 30% (with no change in basal 
OCR) compared to control (Figure 4.5). In addition, amiodarone increased 
basal ECAR by ~ 50% with no increase in ECAR with the stressors (FCCP) 
indicating that amiodarone-treated H9c2 cells are at maximum ECAR at 
basal level (Figure 4.5B). This increased demand for glycolysis, 
mitochondrial respiration and ATP production induced by amiodarone will 
increase risk of cardiomyocytes mitochondrial respiration failure. 
Consequently, these events can lead to the progression of heart failure in the 



















Figure 4.5: Effects of Rosiglitazone and Amiodarone on mitochondrial function in H9c2 cells. H9c2 cells were treated with rosiglitazone (50µM) and 
amiodarone (10µM) for 24hrs. (A) The OCR changes in cells treated with rosiglitazone and amiodarone. (B) The measure of extracellular acidification rate 
(ECAR) showing changes in glycolysis in cells. (C) Peak OCR changes during baseline and stressed conditions. (D) The metabolic phenotypic changes in 





The heart is a vital organ demanding vast amounts of energy to sustain its 
contractile function. Mitochondrial respiration is responsible for generating 
90% of this energy in the form of ATP via the ETC (Li et al, 2002). The ETC 
located in the inner mitochondrial membrane consists of a series of electron 
carriers grouped into four enzyme complexes: complex I (NADH 
dehydrogenase); complex II (succinate dehydrogenase); complex III 
(cytochrome c reductase); and complex IV (cytochrome c oxidase). The 
synthesis of ATP via this respiratory chain involves two coupled processes: 
electron transport and oxidative phosphorylation (OXPHOS) (Wallace, 2003). 
Disruption of cardiac energy homeostasis is a critical feature of DOX-induced 
cardiotoxicity. 
In the current study, diverse drugs groups were examined for cardiotoxicity in 
H9c2 cells in vitro. 
The main important findings of this study were: 
1. All drugs tested (except rosiglitazone) altered metabolic function in 
cardiomyocytes by decreasing peak OCR. 
2. An exception was amiodarone which increased peak OCR and raised 
basal ECAR to peak levels. 
3. Doxorubicin robustly decreased peak OCR which was significantly 
attenuated by melatonin. 
Diverse drugs used for many chronic diseases have limited usage because 
of adverse effects caused by toxicity, in particular to the heart. However, the 
mechanism of cardiotoxicity of these drugs are unclear. The current study 
provided evidence to suggest that one main mechanism of cardiotoxicity is 
via mitochondrial dysfunction. The OCR data for DOX and other cardio toxic 
drugs attenuated the mitochondrial respiration functionality. Oxygen 
consumption rate is lowered most of the drug treatments when compared 
with the control group. The accumulation of drugs in the cardiomyocytes 
directly imposes threat on the mitochondria. In addition, as mentioned 
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previously, these drugs have a high affinity for cardiolipin (Goormaghtighe, 
1980), an integral component of the inner mitochondrial membrane. The 
binding of these drugs to cardiolipin does not allow for cardiolipin interaction 
with key respiratory complexes (Goormaghtighe, 1980) and this could be one 
key mechanism of cardiotoxicity. 
As the inner mitochondrial membrane represents a critical site for drug 
accumulation, the respiratory chain can be considered a potential target for 
drug-induced toxicity. Accumulating studies have demonstrated that cardio 
toxic drugs disrupts mitochondrial respiration at multiple levels, by inhibiting 
complexes of the respiratory chain or inhibiting phosphorylation steps and 
inducing partial uncoupling (Syed-Ahmed et al, 2000). In particular, studies 
aimed at determining the sensitivity of respiratory complexes to cardio toxic 
drugs were found mainly located in complex I, III, and IV, with a specific 
vulnerability for complexes I (NADH dehydrogenase) and IV (cytochrome c 
oxidase) (Marcillat et al, 1989). Additional findings indicate inactivation of 
complex II (Muraoka et al, 2003).The effect of cardiotoxic drugs on 
mitochondrial respiration results in a bioenergetics decline (shown by 
decrease in peak OCR), and is a hallmark of impaired cardiac function in the 
onset and progression of drug-induced cardiotoxicity and heart failure 
Amiodarone is antiarrhythmic drug and chronic usage of the drug leads to 
adverse side effects of sinus rhythm and left ventricular dysfunction (Grosu et 
al, 2018). Rosiglitazone is an anti-diabetic drug but however chronic use 
imposes cardiotoxic effects on the heart causing congestive heart failure, 
chronic hypertension and left ventricular hypertrophy (Chinnam et al, 2012). 
Interestingly, rosiglitazone (50µM) and amiodarone increased the peak OCR 
in H9c2 cells. These results can relate to the long-term usage of the drug 
where the cardiac cells are potentially at a risk of being damaged due to the 
over workload demand. Cardiac tissue requires an uninterrupted supply of 
respiratory substrates to meet the very high ATP demand imposed by 
continuous beating. Over 90% of this ATP is generated by OXPHOS with the 
necessary mitochondrial network taking up approximately one third of 
cardiomyocytes cell volume.  
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Amiodarone and rosiglitazone exert main effects to counteract the effects of 
endogenous catecholamines on myocardial metabolism. They decrease 
cardiac afterload, and increase blood supply to the myocardium which 
compensates for the increase in myocardial oxygen consumption due to the 
increase in myocardial contractility. As a result, there is elevated ROS 
production and mitochondrial membrane potential depolarization. This 
oxygen demand is represented in the OCR data from the Seahorse analyses. 
(Petrosillo et al, 2003; Petrosillo et al, 2009; Nyguen et al, 2012) 
A drug of particular interest is amiodarone which exhibited extremely high 
basal ECAR in H9c2 cells. The high basal ECAR represents high production 
of lactate in the cells through glycolysis. During ATP demand, the cells are 
deprived of oxygen supply and therefore they shift from aerobic to anaerobic 
respiration to meet the ATP demand. Consequently, the limited anaerobic 
metabolism of cardiomyocytes results in a build-up of lactic acid and reduced 
pH in affected areas of the heart. This process of lacto acidosis can induce 
damage to the cardiac cells, which weaken overtime, resulting in impaired 
myocardium contractility and loss of function.  
The common adverse effects of statins are related with muscle soreness, 
fatigue and myopathy.  This leads to muscle damage and affects 
mitochondrial function at cellular level (Auer et al, 2014). Amitriptyline is an 
anti-depressant drug and adverse side effects causes muscle fatigue and 
weakness. Both these drugs have decreased OCR and ECAR. The present 
data provide evidence to support these muscle-related adverse effects may 
be related to the decreased oxygen supply to the cells thus causing muscle 
weakness and damage.  
In conclusion, the present study indicated that a key mechanism of 
cardiotoxicity for diverse drug groups involves altered mitochondrial 
metabolic function. The decreased or increased cellular oxygen consumption 
hinders the efficient respiratory capacity of the cardiomyocytes. It is likely that 
abnormal mitochondrial function, decreased respiratory complex activity, 
increased ROS production, and augmented electron leakage and mPTP 
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opening have all been the main reasons for failing mitochondrial function in 
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Doxorubicin induces cardiac toxicity and cell death in cardiomyocytes during 
acute and long-term treatment which limits its usage. Doxorubicin greatly 
enhance ROS production leading to oxidative stress and subsequent cell 
dysfunction and apoptosis in cardiomyocytes.  
Generally, doxorubicin induces cardio toxicity by exerting effects on the 
mitochondria with increased reactive oxygen species (ROS) production. 
Usually, mitochondria is the site of ROS production and are synthesised as a 
consequence of electrons escaping from electron transport chain and 
captured by oxygen, rendering it to be the home of superoxide production. A 
one-electron reduction of the C ring of DOX results in the formation of a 
semiquinone free radical which, following a reaction with oxygen, produces 
superoxides, peroxides and hydroxyl radicals (Montaigne et al., 2012; Olson 
et al., 1981; Sinha, 1989).  
As a consequence of increased ROS production causes increased oxidative 
stress has a detrimental effect on calcium equilibrium in the cells (Zhang et 
al., 2009). ROS raises calcium levels by promoting its release from the 
sarcoplasmic reticulum. This successively creates a vicious circle where 
elevated Ca2+ levels then increase ROS production through Ca2+-sensitive 
ROS-producing enzymes (Zhang et al., 2009). Since the mitochondria are in 
close proximity to the Ca2+-release site, they are exposed to massive 
quantities of Ca2+ influx. The overwhelming levels of ROS, in conjunction 
with elevated levels of Ca2+ beyond the threshold, trigger the opening of the 
mitochondrial permeability transition pore (mPTP). This causes a loss in 
mitochondrial membrane potential and ultimately the discharge of 
cytochrome c (Zhang et al., 2009). Cytochrome c, situated within the inner 
mitochondrial membrane, (Childs et al., 2002; Chen et al., 2007) forms a part 
of the intrinsic apoptotic pathway. As a result this vicious process of calcium 
mishandling in the cells due to oxidative stress induced by doxorubicin, leads 
to cardiomyocytes cell death. 
The Seahorse studies presented in Chapter 4 demonstrated that DOX-
treatment in H9c2 cells resulted in mitochondrial dysfunction in terms of 
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OXPHOS and glycolysis. Of great interest and clinical relevance, melatonin 
pre-treatment attenuated DOX-induced mitochondrial dysfunction. Melatonin 
has well known function to detoxify ROS and reduce oxidative stress. It acts 
as a powerful anti-oxidant to bring out this effect as a free radical scavenger. 
This powerful feature of melatonin is used to investigate against DOX-
induced apoptosis in cells. However, the protective role of melatonin on 






The aim of this study was to utilise DOX to induce cardiotoxicity and 
apoptosis in H9c2 cells. The potential beneficial effect of melatonin will be 



















5.2 Flow Cytometry results 
 
5.2.1 The Compensation assay 
 
Phospholipids of the cell membrane are asymmetrically distributed between 
the inner and outer leaflets of the membrane. Phosphatidylcholine and 
sphingomyelin are exposed on the external leaflet of the lipid bilayer, while 
phosphatidylserine is located on the inner surface. During apoptosis, this 
asymmetry is disrupted, and phosphatidylserine becomes exposed on the 
outside surface of the plasma membrane. Propidium iodide is used together 
with annexin V-FITC, to differentiate dead cells from dying cells. Binding of 
annexin V correlated with other changes is consistent with apoptosis, 
including changes in nuclear morphology, DNA fragmentation and membrane 
leaflet symmetry. Only cells stained with both annexin V and propidium iodide 
demonstrated chromatin condensation, a late indicator of apoptosis. 
The compensation control assay (carried out for each flow cytometry 
experiment) calibrates the stains which are being used. Compensation is 
required for a flow cytometry experiment because of the physics of 
fluorescence and these controls are used to differentiate the FITC and PI 
stain used in the assay. For each different stain, the compensation works by 
removing the overlap between each stain at a wavelength between 480nm-
675nm in the emission spectrum. A fluorochrome is excited and emits a 
photon in a range of wavelengths in the emission spectrum. Some of those 
photons spill into a second detector, causing single stained samples to 
appear double positive for both stains. Therefore, an application of 
mathematical correction to the data addresses this spill over. This is known 
as compensation. Consequently, this allows distinguishing the different types 
of apoptotic population of cells stained by FITC and PI (Figure 5.1).  
According to manufacturers’ instruction, a DOX concentration that produced 
~50% apoptosis was used for the compensation assay to work. This done to 
make sure the distinguished apoptotic cell population is stained by the FITC 
and PI well enough in order to obtain a reliable reading. Ideally, 0.8µM DOX 
produced ~ 50% apoptosis in H9c2 cells for the compensation controls to 
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work efficiently. The compensation assay was done every time prior a new 
experiment and One- way Anova was used for statistical analysis. 
 
 
Figure 5.1. Compensation controls for DOX-induced apoptosis in H9c2 
cells. Cells were treated with DOX (0.8µM) for 24hrs. Each different stain 
represents the distinguished apoptotic population of cells. Representative 
flow cytometry images are shown. Black (Live cells), Red (Apoptotic cells). 
Similar compensation controls was obtained in each experiment.  
From the compensation data, at 0.8µM Dox, maximum of 50% of apoptosis 
was induced in H9c2 cells over 24hr time period (Figure 5.1). Each quadrant 








5.2.2 Doxorubicin-induced apoptosis in H9c2 cells 
 
Cardiomyocyte apoptosis precedes cardiac dysfunction and heart failure in 
ageing, myocardial infarction, and drug-induced cardiotoxicity. In order to 
examine the beneficial role of melatonin in attenuating DOX-induced cell 
death, the gold standard method of flow cytometry was utilised. The H9c2 
cells were treated with 0.3µM DOX, this concentration was chosen to induce 
20~30% apoptosis in the total viable cell population. Melatonin was used 
alongside to attenuate the effect of doxorubicin.  
 
The data obtained from the Flowing software, represents apoptotic and viable 
cells in respective quadrants- live cells, early apoptosis, late apoptosis and 
necrosis as percentage from the total cell population. 
Doxorubicin (0.3µM, 24 hrs) significantly induced apoptosis (~20%) in H9c2 







Figure 5.2: Melatonin attenuates DOX-induced apoptosis in H9c2 cells in 
flow cytometry assay. Cells were treated with DOX (0.3 µM) with and 
without MEL (1 µM) for 24 hr. Representative data are shown (in duplicate 
wells). Percentages represent total apoptotic cells. Black (Live cells), Red 
(Apoptotic cells) and Pink (Necrotic cells).  
 
The above data is used to replot into bar chart showing the percentage 
apoptosis for each different treatment group. 
                  





















Figure 5.3. Melatonin attenuated doxorubicin-induced cell death in H9c2 
cells in flow cytometry assays. Cells were treated with DOX (0.3 µM) with 
and without MEL (1 µM) for 24 hr. Con: 6.3±0.8%; DOX: 22±1.8%; 
DOX+MEL: 11±1.7%. (n=4 separate experiments in duplicate wells). ANOVA 















Figure 5.4. Doxorubicin and melatonin morphology in H9C2 cardiomyocytes. 
The image above represents the cell viability in each treatment groups. Cell 
viability is reduced in group B, treated with dox (0.5 μM) for 24hrs. In 
presence of melatonin (group c) the cell viability is increased.  Groups A and 
D display similar pattern in terms of cell viability. 
 
 
*Group A = Untreated (control)            *Group C = Dox + Mel (0.5μM + 1μM) 




5.3 Alamar Blue stain cell viability assay  
 
Alamar blue cell viability reagent is a resazurin based reagent. Resazurin is 
the active component in Alamar blue cell viability reagent is a nontoxic, cell 
permeable compound that is blue in colour and fluorescent. Upon entering 
live cells, the cellular reducing environment reduces resazurin to resorufin a 
compound that is red and highly fluorescent. The colour change can be 
detected by absorbance-based plate readers, to deduce cell viability. Alamar 
Blue was used in this experiment to determine cell viability after 24 hr 
treatment with doxorubicin and melatonin. 
Alamar Blue staining was used to determine cell viability after 24 hr treatment 
with DOX and melatonin (summarised in Figure 5.5 and Table 5.1; see 
Appendix C). H9c2 cells treated with DOX (0.5µM, 24 hrs) consistently 
produced reduction in cell viability (~30%). This concentration of the drug 
was chosen to produce similar level of apoptosis as of flow cytometry. Flow 
cytometry assay is relatively more sensitive to measure apoptosis compared 
to Alamar blue cell viability assay. The data is represented as relative 
abundance of the group to the total number of cells with standard error of 
mean. 
Thus, low concentration of Dox (0.3µM) can be used in Flow Cytometry to 
produce the same level of apoptosis at ~ 30%. This effect this was 
completely blocked by melatonin preincubation (1µM, 2hrs) (Figure 5.5). 









Table 5.1:  Melatonin blocked doxorubicin-induced cell death in H9c2 
cells (measured using the Alamar Blue stain method). Data are presented as 
mean±SEM (n=5 separate experiments; each experiment had 3 to 10 
samples). See Appendix C for additional results. 
 
Control Dox Dox + Mel Mel 











































Figure 5.5: Melatonin blocked doxorubicin-induced cell death in H9c2 
cells. Cells were treated with DOX (0.5µM) with and without MEL (1µM) for 
24hr. Data are presented as mean ± SEM (n=5 separate experiments; each 
experiment had 3 to 10 samples). One Way Anova: F (3, 16) = 29.12, P< 









Doxorubicin induced cardiotoxicity involves the dysfunction of mitochondrial 
function via disruption of OXPHOS and glycolysis. In the present study, the 
effect of melatonin on DOX-induced cell death was measured using flow 
cytometry and Alamar Blue staining methods. 
The main important findings of this study were: 
1. Doxorubicin treatment for 24 hours significantly induced H9c2 cell 
death. 
2. Melatonin blocked DOX-induced apoptosis and necrosis as measured 
by two robust measurements of cell viability and apoptosis. 
While toxicity induced by DOX involves multiple factors, the primary 
mechanism of cardiomyocyte cell death is widely believed to be due to DOX-
induced generation of ROS  and concomitant destructive effects of these free 
radicals (Singal et al., 2000). Doxorubicin undergoes redox cycling by 
dehydrogenases like the NADH dehydrogenase enzyme, which is part of the 
mitochondrial complex I. Since cardiomyocytes have an abundance of 
mitochondria, they are especially susceptible to DOX-induced ROS 
generation (Govender et al., 2014).  
Accumulating data have demonstrated that treatment of cardiomyocytes with 
antioxidant compounds prevent ROS formation and toxicity induced by DOX 
(Chularojmontri et al., 2005; Lou et al., 2015; Quiles et al., 
2002; Spallarossa et al., 2004). One of the key events in induction of 
apoptosis is the loss of mitochondrial membrane integrity. The intrinsic 
apoptotic pathway, stimulated by ROS causes a loss of mitochondrial 
membrane potential, leading to the opening of pores in the membrane and 
the leakage of cytochrome c into the cytoplasm. This starts a cascade 
leading to activation of executioner caspases like Caspase-3 and ultimately 
cellular apoptosis (Kalyanaraman et al., 2002). The loss of mitochondrial 
membrane potential gradient is recognized as the point of no return in the 
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apoptotic pathway (Zamzami et al., 1995), underlining the importance of this 
event. One of the ways DOX is thought to mediate cardiac cell apoptosis is 
through the intrinsic pathway, initiated in the mitochondria (Hsu et al, 2014).   
It is well documented that melatonin acts as an effective antioxidant in 
various in vitro and in vivo models of cardiac diseases not only by 
scavenging free radicals but also by increasing the gene expression of 
antioxidative enzymes like GPx, GR, and SOD (Wang, 2009). Melatonin 
exerts its antiapoptotic activity by its known ability to inhibit release of 
cytochrome c from Ca2+ mediated mitochondria (Rhao et al, 2014). 
Mitochondria membrane potential is crucial factor for the maintenance of 
cellular bioenergetics homeostasis and its dissipation leads to formation of 
mitochondrial permeability transition pore (mPTP) in cardiotoxicity. Melatonin 
increased the expression of antiapoptotic proteins like bcl-2 through SIRT1 
pathways and also decreased the expression of apoptotic factor Bax (Wang 
et al, 2009; Sims and Muyderman, 2010; Li et al, 2014; Yang et al, 2015). 
Therefore melatonin maintains the mitochondrial membrane potential in 
cardiomyocytes and indirectly inhibits the opening of the mPTP (Gouriou et 
al, 2013). It will be of interest to examine the possible mechanisms of action 
of melatonin in protecting H9c2 cells from DOX-induced cell death (see 
Chapter 6). 
In conclusion the beneficial effects of melatonin administration against these 
conditions are in part due to its direct free radical scavenger activity and its 
indirect antioxidant properties. The data obtained from the current study 
(chapters 4 and 5) provide evidence demonstrating   the effect of melatonin 
on mitochondrial bioenergetics and its role in anti-apoptosis. This will 
undoubtedly provide novel insight that will deepen our understanding of 
melatonin’s protective mechanisms during DOX-induced cardiotoxicity. It is 
recommended that in the future, the therapeutic value of melatonin in the 
treatment of DOX-induced cardiotoxicity will be useful to assess 
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Doxorubicin is a potent drug used to treat several cancers including 
carcinomas and sarcomas (Thorn et al., 2011). Although effective, the 
adverse effect of DOX limits its clinical use. Patients are affected by 
DOX-induced cardiotoxicity in a dose-dependent manner and may 
present to the clinic with a serial decline in ventricular ejection fraction 
and reduced contractile function with associated diastolic dysfunction 
(Chatterjee et al., 2010; Thorn et al., 2011). The DOX-induced 
morphological and functional abnormalities of the cardiac tissue results in 
irreversible dilated cardiomyopathy which once established, may 
progress into biventricular congestive heart failure; carrying a poor 
prognosis of approximately 50% mortality (Chatterjee et al., 2010).  
The acute effect of DOX can occur within few hours to days. This results in 
the early stages of arrhythmia and apoptosis. Malignant arrhythmias account 
for a significant portion of heart failure related deaths (Sadredini et al, 2016). 
The exact mechanisms of DOX-induced cardiotoxicity is unclear but it will 
involve disruptions in multiple diverse signalling pathways such as apoptosis, 
cardiac hypertrophy and cardiomyopathy, mitochondrial dysfunction and 
cardiac electrical remodelling (Troidl et al, 2009; Cheung et al, 2015; 
Tarradas et al, 2017; Haque and Wang, 2017). 
Apoptosis is initiated and executed through two major signalling pathways: 
the intrinsic and extrinsic pathways. Intrinsic apoptosis pathway (also named 
as mitochondrial apoptosis pathway) is triggered by intracellular stress such 
as oxidative stress, calcium overload, and DNA damage, leading to Bax/Bak-
dependent mitochondrial outer membrane permeabilization and release of 
cytochrome c from mitochondria into cytosol. Cytosolic cytochrome c and 
apoptotic protease-activating factor 1 (Apaf-1) then form apoptosome and 
result in activation of caspase 9. The intrinsic pathway firmly controlled by the 
Bcl-2 protein family including anti- apoptosis Bcl-2, Bcl-xL, pro- apoptosis 
Bax, Bak. Mitochondrial uncoupling protein 2 (UCP2) is the most studied 
protein in its family of mitochondrial anion carrier proteins. Mitochondrial 
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uncoupling proteins are located in the mitochondrial inner membrane which 
can promote the proton leak across the mitochondrial inner membrane and 
provide protection via p38 signalling pathway (Dong et al, 2014; Zhang et al, 
2018). 
Intermediate effect of DOX can take place from weeks to months which can 
lead to remodelling of the heart. Myh7 gene encodes beta (β)-myosin heavy 
chain (β-MHC). In cardiac muscle cells β-MHC forms part of a large protein 
known as type II myosin and it is responsible for the interaction with actin 
protein for cell movement and shape. During cardiotoxicity the gene 
disruption causes up-regulation of β-MHC with corresponding down-
regulation of α-MHC. This happens through p38 MAPK, extracellular signal-
regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) signalling 
pathways. Cardiac remodelling could lead to the development of 
hypertrophy in the heart. 
The chronic effect of DOX takes months to years progressing towards heart 
failure. In heart failure, an excessive preload overwhelms the contractility of 
the heart, resulting in decreased cardiac output characterized by both 
systolic and diastolic function. Serca2a is a fundamental protein involved in 
the process of removing Ca2+ into the sarcoplasmic reticulum during diastole. 
Serca2a transports the Ca2+ released during ECC back into the SR lumen 
against the electrochemical [Ca2+] gradient using chemical energy from 
ATP. However, in heart failure there is a reduction of Serca2a protein level 
and function. It seems to act via the Serca2a attenuating calcium overload 
via ERK1 pathway (Tarradas et al, 2017). 
MS1 is a myofibrillar protein involved in the regulation of gene expression in 
both cardiac and skeletal muscle. It is also known as striated muscle 
activator of Rho Signalling and Serum Response Factor dependent 
transcription (STARS) (Arai et al, 2002) or Actin-binding Rho-activating 
protein (ABRA) (Troidl et al, 2009). 
The signalling pathway of JNK and MAPKs are disrupted and the changes 
affect the transcription of the MS1 gene leading to the down regulation of the 
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The aim of the present study was to delineate the mechanisms of action of 
doxorubicin-induced cardiotoxicity and melatonin action by examining altered 




























6.2 Results - Semi quantitative PCR analysis 
 
In the present study, gene expression was analysed under four conditions in 
H9c2 cells: control group (no drugs added); DOX group; DOX+MEL group 
(cells pre-treated with melatonin and then DOX); Melatonin alone. The 
concentration of DOX used is 0.5 µM, this concentration was used similar to 
previous experiments used for apoptosis studies. 
Image J software was used to quantify the PCR fragments of the gel image 
for the genes. The colour of the gel image was first inverted (PCR fragments 
are black in a white background) and then each PCR fragment was selected 
and analysed. The arbitrary numerical value for each PCR fragment was 
calculated and then the percentage of each peak on the plot was calculated. 
This gave an arbitrary value for each gene from separate experiments. The 
expression levels of each experimental sample (per gene) were divided by 
expression levels of the internal control gene (Cyclophillin A) and these ratios 
plotted and analysed. See Appendix B, for results. 
In order to identify putative mechanisms of action of DOX-induced 
cardiotoxicity and melatonin action, candidate genes that are involved in the 
progression of heart failure will be measured. These genes are categorised 
here in five main groups with overlapping functions: cardiac conductivity, 











6.2.1 CAV3  
 
DOX-treatment of H9c2 cells significantly decreased CAV3 gene expression 
which was modestly attenuated by melatonin but it was not statistically 
significant (Figure 6.1). 
 































































A p = 0 .0 0 7 6
p = 0 .1 4 2 5
p = 0 .1 4 3 0
 
Figure 6.1. Melatonin attenuates doxorubicin downregulation of CAV3 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 16.57, P=0.0009. Data considered 
statistically significant at p≤0.05. 
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Doxorubicin robustly decreased Drp1 mRNA expression in H9c2 cells which 


































































p = 0 .0 0 5 0
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Figure 6.2. Melatonin attenuates doxorubicin downregulation of Drp1 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 4.19, p=0.0467. Data considered 









Mfn1 gene expression was significantly decreased by DOX-treatment in 
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Figure 6.3. Melatonin attenuates doxorubicin downregulation of Mfn1 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 1.88, p=0.2112. Data considered 










Dox-treatment deceased PPAR-γ gene expression in H9c2 cells which was 
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p = 0 .0 0 7 2
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Figure 6.4. Melatonin attenuates doxorubicin downregulation of PPAR-γ 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 10.36, p=0.0040. Data considered 
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Doxorubicin alone (0.5µM, 24 hrs) had no significant effect on Sirt3 gene 
expression in H9c2 cells (Figure 6.5). However under DOX-induced stress, 
melatonin modestly increased Sirt3 gene expression. Melatonin alone also 
significantly increased Sirt3 mRNA expression compared to the untreated 
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Figure 6.5. Melatonin enhanced Sirt3 gene expression under 
doxorubicin-induced stress in H9c2 cells. Cells were DOX -treated (0.5 
µM, 24 hrs) with and without melatonin (1µM). The results presented are 
mean ± SEM, n= 3. One-Way ANOVA: F (3, 8) = 7.77, p=0.0094. Data 
considered statistically significant at p≤0.05. 
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6.2.6. Parp 1 
 
Melatonin attenuates Dox-induced downregulation of Parp 1 mRNA in H9c2 
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Figure 6.6. Melatonin attenuates doxorubicin downregulation of Parp 1 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 25.51, p=0.0002. Data considered 
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6.2.7. Parp 2 
 
Melatonin attenuates DOX-induced downregulation of Parp 2 mRNA in H9c2 
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Figure 6.7. Melatonin attenuates doxorubicin downregulation of Parp 2 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 29.95, p=0.0001. Data considered 
statistically significant at p≤0.05. 
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Doxorubicin robustly decreased ms1 mRNA expression in H9c2 cells (Figure 
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Figure 6.8. Melatonin attenuates doxorubicin downregulation of Ms1 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 12.86, p=0.0020. Data considered 
statistically significant at p≤0.05. 
 
In order to confirm the authenticity of the semi-quantitative gene analysis 
study, Ms1 was measured using real-time qPCR (Figure 6.9). 
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F (3, 4) = 109.5 P=0.0003
P =  0 .0 0 0 2
P =  0 .0 0 6 5
 
Figure 6.9: Melatonin attenuates doxorubicin-induced downregulation 
of Ms1 gene expression in H9c2 cells measured using quantitative PCR. 
. Cells were DOX -treated (0.5 µM, 24 hrs) with and without melatonin (1µM).  
The results presented are mean ± SEM, n= 3. One-Way ANOVA: F (3, 4) = 















Doxorubicin treatment decreased the expression of Serca2a mRNA in H9c2 
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Figure 6.10. Melatonin attenuates doxorubicin downregulation of 
Serca2a gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 
24 hrs) with and without melatonin (1µM). The results presented are mean ± 
SEM, n= 3. One-Way ANOVA: F (3, 8) = 4.20, p=0.0464. Data considered 
statistically significant at p≤0.05. 
 
In order to confirm the authenticity of the semi-quantitative gene analysis 
study, Serca2a was measured using real-time qPCR (Figure 6.11). 
Serca2a 
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F (3, 6) = 138.9 P<0.0001
P =  0 .0 0 0 1
P =  0 .0 0 0 1
 
Figure 6.11: Melatonin blocks doxorubicin-induced downregulation of 
Serca2a gene expression in H9c2 cells measured using quantitative 
PCR. Cells were DOX -treated (0.5 µM, 24 hrs) with and without melatonin 
(1µM). The results presented are mean ± SEM, n= 3. One-Way ANOVA: F 















Doxorubicin-induced stress dramatically increased Scn5a gene expression in 
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Figure 6.12. Doxorubicin-induced stress increased Scn5a gene 
expression which was blocked by melatonin in H9c2 cells. Cells were 
DOX - treated (0.5 µM, 24 hrs) with and without melatonin (1µM). The results 
presented are mean ± SEM, n= 3. One-Way ANOVA: F (3, 8) = 7.60, 
p=0.0100. Data considered statistically significant at p≤0.05 
 
In order to confirm the authenticity of the semi-quantitative gene analysis 









































F (3, 8) = 13.3 P=0.0018
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Figure 6.13:  Melatonin blocked Dox-induced upregulation of Scn5a 
gene expression in H9c2 cells using quantitative PCR. Cells were DOX -
treated (0.5 µM, 24 hrs) with and without melatonin (1µM). The results 
presented are mean ± SEM, n= 3. One-Way ANOVA: F (3, 8) = 13.3,  



















Doxorubicin-induced stress dramatically increased Myh7 gene expression in 
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Figure 6.14. Doxorubicin increased Myh7 gene expression which was 
partially reversed by melatonin in H9c2 cells. Cells were DOX - treated 
(0.5 µM, 24 hrs) with and without melatonin (1µM). The results presented are 
mean ± SEM, n= 3. One-Way ANOVA: F (3, 8) = 5.61 and p=0.0228. Data 
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6.2.12. UCP 2 
 
Doxorubicin decreased UCP2 gene expression in H9c2 cells which was 
attenuated by melatonin. Of interest, melatonin alone significantly increased 
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Figure 6.15. Melatonin attenuates doxorubicin downregulation of UCP2 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 35.02 and p=0.0001. Data considered 
statistically significant at p≤0.05. 
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In order to confirm the authenticity of the semi-quantitative gene analysis 
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Figure 6.16: Melatonin blocks doxorubicin-induced downregulation of 
UCP2 gene expression in H9c2 cells. Cells were DOX -treated (0.5 µM, 24 
hrs) with and without melatonin (1µM).   The results presented are mean ± 
SEM, n= 3. One-Way ANOVA: F (3, 8) = 10.38 and p=0.0039. Data 















Doxorubicin-induced stress increased Bcl2 gene expression in H9c2 cells 
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Figure 6.17. Melatonin attenuates doxorubicin downregulation of Bcl2 
gene expression in H9c2 cells. Cells were DOX - treated (0.5 µM, 24 hrs) 
with and without melatonin (1µM). The results presented are mean ± SEM, 
n= 3. One-Way ANOVA: F (3, 8) = 33.38 and p=0.0001. Data considered 
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Melatonin enhanced Bcl-xL gene expression in H9c2 cells under DOX-
















Figure 6.18. Melatonin enhanced Bcl-xL gene expression in H9c2 cells 
under doxorubicin-induced stress.  Cells were DOX -treated (0.5 µM, 24 
hrs) with and without melatonin (1µM). The results presented are mean ± 
SEM, n= 3. One-Way ANOVA: F (3, 8) = 69.67 and p=0.0001. Data 
considered statistically significant at p≤0.05. 
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The global use of some anti-cancer drugs (in particular DOX) has been 
limited because of their common adverse effect of cardiotoxicity including 
heart failure. In the current project, DOX has been shown to cause acute 
mitochondrial dysfunction in OXPHOS and glycolysis (Chapter 4). Cell 
viability assays have demonstrated that DOX-treatment significantly induced 
apoptosis in H9c2 cells (Chapter 5). Interestingly, melatonin pre-treatment 
dramatically inhibited the deleterious effect of DOX on cardiac cell function 
and survival. However, the putative mechanisms of action of melatonin in 
these processes are unknown. In the current chapter, altered gene 
expression profiles were examined in DOX-treated cells. 
The main important finding of this study was: 
1. Doxorubicin treatment altered gene expression in fundamental 
biological processes such as mitochondrial function, cardiac electrical 
coupling, cell survival, cardiac remodelling and heart failure.  
2. Melatonin treatment has mainly attenuated or blocked the negative 
effect of DOX-treatment. 
 
H9c2 cells were treated with doxorubicin (0.5µM) and melatonin (1µM) for 
24hrs. The semi-quantitative PCR technique screened for several genes 
involved in mitochondrial dysfunction, apoptosis, arrhythmias, cardiac 
remodelling and heart failure. Gene expression was studied among the 
genes of interest to determine if doxorubicin can alter gene expression and if 
melatonin was able to attenuate this effect.  
ROS production from mitochondrial respiration is triggered by doxorubicin, 
affecting the ATP production in the cells and leading to mitochondrial 
dysfunction. During this process certain mitochondrial related genes 
becomes affected and starts to express differently (Kiyuna et al, 2018). The 
genes of interest in mitochondrial dysfunction were Cav3, Mfn1, Drp1, Parp1, 
Parp2 and Sirt3. The data represented that doxorubicin treatment 
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downregulated the expression of all these genes when compared with the 
control group. In the presence of melatonin, the genes were upregulated and 
restored back to functionality. 
Cardiac arrhythmias account for a significant portion of heart failure related 
deaths (Sadredini et al, 2016). Arrhythmias are mostly caused by calcium 
mediated premature action potentials that arise from so called early or 
delayed after depolarisations. These heart beats cause premature ventricle 
contractions or short runs of ventricular tachycardia, such as long QT 
syndrome (Tse, 2016). The target gene involved in arrhythmia is Scn5a 
which is upregulated by doxorubicin induced cardiotoxicity to attain gain of 
function state which causes ventricular arrhythmias. In the presence of 
melatonin, the gene is downregulated and the functionality is restored. 
Cardiomyocytes apoptosis is one of the latter stages in heart failure. 
Myocardial impairment induced by doxorubicin may involve myocyte 
apoptosis mediated by oxidative free radical formation (Kotamraju et al, 
2000). Anti-apoptotic genes, Bcl2, Bcl-xL and UCP2 were downregulated by 
doxorubicin when compared with control and melatonin attenuates this effect.  
The myocardial injury after arrhythmias and apoptosis (triggered by 
doxorubicin) leads to the development of cardiac remodelling involving the 
increase of the left ventricular cavity. The cardiac structure changes 
influencing the left ventricular function. Cardiomyocytes become enlarged to 
increase muscle mass to reduce wall stress (Watkins et al, 2011). Mutations 
in β-Myosin heavy chain encoded by the gene Myh7 which is upregulated 
and can be seen in left ventricular hypertrophy. Nuclear receptor 
transcription factors regulate cardiac metabolism, among them PPAR-ꝩ is 
downregulated in the remodelling of the heart. In addition Ms1 is a 
myofibrillar protein in cardiac muscle and involved in cardiac remodelling 
and the hypertrophic response. The gene is downregulated in response 
towards cardiac remodelling. 
Following cardiac remodelling the final stage ends in heart failure. An 
excessive preload overwhelms the contractility of the heart, resulting in 
decreased cardiac output characterized by both systolic and diastolic 
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function. In heart failure there is a disturbed mitochondrial calcium cycling, 
which involves Serca2a gene involved in removing Ca2+ into the 
sarcoplasmic reticulum during diastole. This gene is downregulated in heart 
failure with loss of function.  
A newly identified protein that is essential for cardiac development and stress 
response is ms1. MS1 is a myofibrillar protein involved in the regulation of 
gene expression in both cardiac and skeletal muscle. It is also known as 
striated muscle activator of Rho Signalling and Serum Response Factor 
dependent transcription (STARS) (Arai et al, 2002) or Actin-binding Rho-
activating protein (ABRA) (Troidl et al, 2009). It is highly involved in cardiac 
remodelling and the hypertrophic response. Cardiomyocytes under 
physiological stress take adaptive responses via activation of Mitogen-
Activated Protein Kinase (MAPK) pathways. These pathways mediate 
changes in gene expression by targeting transcription factors, including those 
that activate the SRE (Kyriakis et al, 2012). The stress-activated MAPKs, c-
Jun N-terminal Kinase (JNK) and p38-MAPK, are activated strongly by 
cardiac ischaemia/reperfusion injury.  
Both the JNK and p38 pathway are involved in mediating diverse adaptive 
responses in myocytes, including protection from redox stresses, ischaemic 
preconditioning and the induction of muscle hypertrophy. MS1 induction by 
mechanical loading activates downstream stress-responsive pathways 
converging on ternary complex factors (TCF)/SRF, which are a known target 
of stress-activated MAPKs such as JNK (Whitmarsh et al, 1997; Kuwahara et 
al, 2005). MS1 had shown reduced expression in H9c2 cells under 
doxorubicin treatment. It is known that MS1 promoter may be a downstream 
target for the JNK signalling pathway.The MS1 promoter has been 
characterised in some detail with binding sites for several transcription 
factors having been identified and some of these may be JNK targets (Chong 
et al, 2012; Ounzain et al, 2012). Of particular interest is an SRF binding site 
at an SRE located 305 base pairs upstream of the transcription start site 
(Chong et al, 2012). SRF is known to interact with a family of TCFs which are 
directly phosphorylated by JNK and other MAPKs, thus providing a possible 
mechanism for JNK mediated regulation of the MS1 promoter. In the 
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presence of DOX-induced stress it is conceivable that the signalling pathway 
of JNK and MAPKs are disrupted and the changes affect the transcription of 
the ms1 gene leading to downregulation and whereby melatonin may 
interfere with this pathway to attenuate the downregulation of ms1. 
Calcium mishandling is a critical hallmark of cardiac dysfunction and heart 
failure; one key factor essential for calcium homeostasis in cardiomyocytes is 
SERCA2a. SERCA2a is thought to have physiologically strategic and 
intricate roles in cardiac electrophysiological and mechanical function. Its 
diastolic translocation of released Ca2+ from cytosol to SR minimizes 
cytosolic [Ca2+]. This ensures full myocardial relaxation, a normal ventricular 
diastolic compliance and filling, and minimizes delayed after-potentials that 
would otherwise compromise membrane electrophysiological stability. These 
functions thus prevent the diastolic dysfunction and arrhythmic tendency 
characteristic of cardiac failure (Huang, 2013). 
Doxorubicin is a major contributory factor for the death of cardiomyocytes, 
including oxidative stress, calcium overload and mitochondrial permeability 
transition pore (mPTP) opening. Calcium overload results in part from 
excessive sarco/endoplasmic reticulum (SR/ER) Ca2+ release and Ca2+ influx 
through the plasma membrane. Impaired calcium reuptake resulting from 
decreased expression and activity of SERCA2a is a hallmark of HF.  
Doxorubicin is known to modulate the PI3K/Akt and the MAPK/ERK1/2 
signalling pathways itself and may contribute to its cardiotoxicity. PI3K/Akt is 
known to reduce oxidative stress and decrease mPTP opening (Maulik et al, 
2018). Hu and colleagues (2018) have shown that H9C2 cells undergoing 
simulative hypoxia/reoxygenation (H/R) induction and they observed 
melatonin treatment promoted phosphorylation of ERK1 in cardiomyocytes 
against H/R. To further elucidate the underlying mechanism for protective 
effect of melatonin cardiomyocytes against H/R, Hu et al (2018) observed the 
effects of melatonin on expression of SERCA2a. Their results showed 
SERCA2a expression is decreased during H/R and melatonin inhibited the 
downregulation of SERCA2a due to H/Rin cardiomyocytes. In vivo studies 
further confirmed that melatonin regulates the expression of SERCA2a via 
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ERK1 (Gomez et al, 2016; Hu et al, 2018). Therefore, one of the mechanism 
by which melatonin protect cardiomyocytes against reperfusion injury and 
oxidative stress maybe through modulation of SERCA2a, attenuating calcium 
overload via ERK1 pathway. 
An immediate adverse effect of DOX-treatment in humans is cardiac 
arrhythmias, which can be lethal. A key factor that regulates the correct 
electrical firing and coupling of the cardiac action potential (AP) is a protein 
called Scn5a. Scn5a gene is member of the human voltage-gated sodium 
channel gene family and encodes alpha subunit of the main cardiac sodium 
channel Nav1.5. Nav1.5 is known to be responsible for maintaining the normal 
function of inward sodium current.  Scn5A −/− mice are not viable, 
while Scn5A +/− knockout mice display cardiac conduction defects and 
ventricular tachycardia (Papadatos et al, 2002). 
Doxorubicin induced free radical formation in mitochondria and sarcoplasmic 
reticulum alters the membrane potential of the sodium gated ion channels 
(Nordgren et al., 2017). Sodium current participates in phase 0 and 2 of the 
AP, which is an important determinant on the production of heart rhythms, 
normal conduction, and maintenance of excitement. As a result, the 
SCN5A variants would potentially cause disorganisation of the cardiac 
electrophysiological system, produce various arrhythmias and result in 
structural heart diseases due the loss of function and gain of function states 
(Onwuli et al, 2017). The gain of function state of Scn5a increase intracellular 
sodium concentration thereby causing a secondary increase in intracellular 
calcium that, in turn, leads to cellular remodelling, arrhythmia and heart 
failure (Zhang et al, 2018).  
Recently a study has shown that SCN5A expression is regulated by the 
GATA4 transcription factor in the human heart. GATA4 synergises 
with GATA5 in the activation of the SCN5A gene via binding to GATA-BS 
within the SCN5A proximal promoter and intron 1 regions. GATA4 is 
considered a master regulator of cardiac transcriptional networks and plays a 
key role in cardio genesis and in adult cardiac cells (Tarradas et al, 2017). Of 
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interest, Ouzain and colleagues (2012) have demonstrated that GATA4 
negatively regulates MS1 expression in striated muscle cells.  
Genetic variants in GATA4 (or GATA5) genes could be related to 
arrhythmogenic diseases via dysregulation of SCN5A expression. The effect 
of mutations on GATA4 (and GATA5) function could determine the levels of 
NaV1.5 channel expression, which could explain the variability of phenotypes 
associated with SCN5A-related arrhythmias. At present the mechanism 
whereby DOX induced Scn5a expression in cardiomyocytes is unknown. 
However, it is reasonable to suggest that it can affect the transcription factors 
GATA 4 and GATA 5 which in turn can regulate SCN5a gene expression. 
Melatonin provides protection against DOX-induced cardiac 
electrophysiology uncoupling via balancing gene alteration such as changes 
in Scn5a expression.  
Metabolic dysfunction in the heart is a key disorder and contributing factor to 
progressive heart failure. Uncoupling proteins, such as UCP2, are cationic 
carrier protein which plays an important role in regulation of metabolism, for 
example ROS production, glucose control and immunity and implicated 
pathologies such as heart failure, diabetes, and cancer (Harper et al, 2004). 
Uncoupling proteins are located in the mitochondrial inner membrane which 
can promote the proton leak across the mitochondrial inner membrane. It is 
an essential regulator of mitochondrial membrane potential, that disperse the 
mitochondria proton gradient by translocating H+ across the inner 
membrane, following with respiratory activity, ROS and ATP generation (Yu 
et al, 2000). A study on the mechanism of melatonin on DOX-induced 
cardiotoxicity in relation to UCP2 expression is unknown. The current study 
indicated that DOX dramatically reduced UCP2 expression which was 
blocked by melatonin. Indeed, melatonin alone significantly increased basal 
UCP2 mRNA levels compared to untreated control cells.   
The precise mechanism whereby UCP dysfunction may lead to heart failure 
is unclear. Wang et al. (2018) recently demonstrated that DOX interacts with 
general control nonderepressible 2 (GCN2), a protein kinase that modulates 
amino acid metabolism in response to nutrient deprivation caused by cellular 
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stress (Anda et al., 2017). This interaction leads to decreased expression of 
UCP2 as well as Bcl-2 and subsequently initiated cell death and heart failure 
(Figure 6.19). Data from the current project supports the notion that the 
presence of enough melatonin may reduce oxidative stress in the 
mitochondria by inhibiting the activation of GCN2 by DOX. This may be 
through its antioxidant mechanism through ROS scavenging and MPTP 
inhibition as well as UCP2 gene activation (Tan et al., 2016). In turn, the 
activated UCP2 prevents cardiomyocytes damage by inducing proton leak in 
inner mitochondrial membrane to reduce mitochondrial membrane potential 
to increase oxygen consumption as demonstrated in previous studies 
(Pecquer et al., 2002; Moon et al., 2015).  
Chen and colleagues (2018) provided additional data to support the role that 
UCP2 is an anti-apoptotic factor in H9c2 cells.  UCP2 knockdown induced 
apoptosis whereas a drug which induced UCP2 expression (ursolic acid) 
attenuated hypoxia-reoxygenation induced apoptosis via a protective p38 
signalling pathway. 
Thus, UCP2 homeostasis is modulated by melatonin to decrease DOX-
induced oxidative stress due to melatonin’s mitochondrial targeted 
antioxidants initiating mitochondrial protection via UCP2 activation, to reduce 
cardiomyocytes oxidative stress. Of interest, the present project has also 
demonstrated that DOX reduced Bcl2 expression in H9c2 cells which was 






Figure 6.19.  A putative mechanism of the cardio protective role of 
melatonin involving UCP2. Doxorubicin interacts with GCN2 and activates 
to cellular stress response which initiates decrease in UCP2. Melatonin may 
reduce cellular stress by inhibiting the activation of GCN2 by doxorubicin via 
ROS scavenging and inhibiting mPTP opening, reducing cellular stress, 
which in turn may increase UCP2 and reduce cell death and heart failure 































A major global limitation of drug intervention in chronic diseases is organ 
damage such as cardiotoxicity. More than 30% of new drug candidates do 
not progress beyond phase I clinical trials because of cardiac complications. 
Indeed, more medicine are being identified as cardio toxic with the use of 
sensitive assays such as utilisation of human induced pluripotent stem cells 
derived cardiomyocytes and high-throughput electrophysiology screening 
techniques. However, the molecular and cellular mechanisms of drug-
induced cardiotoxicity, in particular anti-cancer drugs, are unclear and mostly 
unknown. 
 
In the present project, the metabolic dysfunctions in cardiomyocytes caused 
by groups of commonly used drugs were examined using the Seahorse 
assay. Using flow-cytometry and Alamar Blue staining methods, 
cardiomyocyte cell death caused drug-treatment was investigated.  Finally, a 
putative gene pathway that may be central in drug-induced cardiotoxicity was 
delineated using PCR. Accumulative evidence demonstrated that the pineal 
hormone melatonin may play a beneficial role in cardio-protection and this 
was examined in the current project. 
 
The main important findings of the current study were: 
1.    Diverse drugs including anti-depressants, anti-cancer, anti-cardiac 
arrhythmia, and statins, altered mitochondrial activity (OXPHOS, 
glycolysis) and compromised cardiomyocyte function. 
2.    Mitochondrial dysfunction caused by cardio toxic chemicals which 
induce oxidative stress (Isoproterenol, hydrogen peroxide) which was 
attenuated by melatonin treatment. 
3.    Doxorubicin, a commonly used anti-cancer drug robustly caused 
mitochondrial dysfunction and apoptosis in cardiomyocytes, was 
robustly blocked by melatonin.  
4. Doxorubicin-treated cardiomyocytes dramatically altered gene 
expression in diverse regulatory pathways in apoptosis, metabolism, 
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cardiac conductivity, cardiac remodelling and heart failure. Melatonin 
pre-treatment attenuated these changes in gene expression. 
 
In this study, H9c2 cells were examined under a diverse range of drugs. 
Hydrogen peroxide (200µM) and isoproterenol (10µM) are potent stress 
inducers in cardiomyocytes. They mimic ischemic conditions in cells by 
inducing oxidative stress (Ojha, 2010). Cardiotoxic drugs such as statins 
(10µM), doxorubicin (0.1µM), amiodarone (10µM), amitriptyline (10µM) and 
rosiglitazone (50µM) exert their toxic characteristics in cells to disrupt the 
metabolic function of the mitochondria and hinder the ATP production of the 
cells. 
Cardiac cell function and metabolism is hindered by cardiotoxicity. The 
accumulation of drugs in the cardiomyocytes directly imposes threat on the 
mitochondria. As mentioned previously in above chapters, these drugs have 
a high affinity for cardiolipin (Goormaghtigh, 1980), an integral component of 
the inner mitochondrial membrane. The binding of these drugs to cardiolipin 
does not allow for cardiolipin interaction with key respiratory complexes 
(Goormaghtigh, 1980). During normal physiological conditions, ROS are 
generated at very low levels, but can increase dramatically in 
pathophysiological conditions such as myocardial ischaemia/reperfusion (I/R) 
injury and cardiotoxicity (Paradies et al, 2010), causing a loss in the 
phospholipid cardiolipin, which in turn, is responsible for the loss of activity of 
the respiratory chain complexes I, III and IV (Paradies et al, 1999; Lochner et 
al, 2015). In particular, studies aimed at determining the sensitivity of 
respiratory complexes to cardio toxic drugs were found mainly located in 
complex I, III, and IV, with a specific vulnerability for complexes I (NADH 
dehydrogenase) and IV (cytochrome c oxidase), where there is an increased 
production of ROS (Marcillat et al, 1989). In addition mPTP opening is crucial 
in mitochondria where under normal circumstances, mPTP opening is closed 
preventing the loss of electrons and cytochrome c, however, cardiotoxic 
drugs have the ability to cause the opening of mPTP and disrupting the 
mitochondrial function.  
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Melatonin and its metabolites have the free radical scavenging abilities and 
acts as a robust anti-oxidant for the cells (Favero et al, 2017). The major 
target of melatonin is to inhibit the opening of the mitochondrial transition 
pore opening (MPTP). The opening of the MPTP is crucial for the apoptosis 
and necrosis of the cells with the release of cytochrome c. Melatonin 
effectively inhibits the opening of the MPTP and prevents the cells 
undergoing apoptosis during ischemia (Reiter et al, 2016). 
Petrosillo and co-workers have demonstrated convincingly that melatonin 
effectively protects against I/R damage and the protection afforded by 
melatonin against mitochondrial dysfunction was associated with 
improvement in functional recovery during reperfusion (Petrosillo et al, 2003). 
The follow up work done in 2009, by the same group, found melatonin 
protects cardiomyocytes by inhibiting MPTP opening in the mitochondria 
(Petrosillo et al, 2009). It is generally accepted that melatonin exerts its 
cardio protective actions via its free radical scavenging activities as well as 
the induction of anti-oxidant enzymes (Hardeland, 2005; Cardinali et al, 
2006). It is likely that abnormal mitochondrial function, decreased respiratory 
complex activity, increased ROS production, and augmented electron 
leakage and mPTP opening have all been the main reasons for failing 
mitochondrial function in the pathophysiology of drug-induced cardiotoxicity, 
however, melatonin has shown the potential to attenuate these effects and 
improve the functionality of the mitochondria much more efficiently within this 
acute time period. 
Therefore, the drugs examined in the present thesis imposed direct metabolic 
dysfunction in cardiac cells affecting OXPHOS and glycolysis in 
cardiomyocytes by having an impact on the mitochondrial respiratory 
complexes. On the other hand, melatonin and its metabolites have the free 
radical scavenging abilities and acts as a robust anti-oxidant for the cells 
against cardiotoxicity (Favero et al, 2017). It improves the metabolic functions 
of the cell and inhibits the opening of mPTP which is crucial for maintaining 




Futhermore, H9c2 cells were treated with doxorubicin (0.5µM) and melatonin 
(1µM) for 24hrs. The semi-quantitative PCR technique screened for several 
genes involved in mitochondrial dysfunction, apoptosis, arrhythmias, cardiac 
remodelling and heart failure. Gene expression was studied among the 
genes of interest to determine if doxorubicin can alter gene expression and if 
melatonin was able to attenuate this effect.  
ROS production from mitochondrial respiration is triggered by doxorubicin, 
affecting the ATP production in the cells and leading to mitochondrial 
dysfunction. During this process certain mitochondrial related genes 
becomes affected and starts to express differently (Kiyuna et al, 2018). The 
genes of interest in mitochondrial dysfunction were Cav3, Mfn1, Drp1, Parp1, 
Parp2 and Sirt3. The data represented that doxorubicin treatment 
downregulated the expression of all these genes when compared with the 
control group. In the presence of melatonin the genes were upregulated and 
restored back to functionality. The target gene involved in arrhythmia is 
Scn5a which is upregulated by doxorubicin induced cardiotoxicity to attain 
gain of function state which causes ventricular arrhythmias. In the presence 
of melatonin, the gene is downregulated and the functionality is restored. 
Cardiomyocytes apoptosis is one of the latter stages in heart failure. 
Myocardial impairment induced by doxorubicin may involve myocyte 
apoptosis mediated by oxidative free radical formation (Kotamraju et al, 
2000). Anti-apoptotic genes, Bcl2, Bcl-xL and UCP2 were downregulated by 
doxorubicin when compared with control and melatonin attenuates this effect.  
The myocardial injury after arrhythmias and apoptosis (triggered by 
doxorubicin) leads to the development of cardiac remodelling involving the 
increase of the left ventricular cavity (Watkins et al, 2011). Mutations in β-
Myosin heavy chain encoded by the gene Myh7 which is upregulated and 
can be seen in left ventricular hypertrophy. Nuclear receptor transcription 
factors regulate cardiac metabolism, among them PPAR-ꝩ is downregulated 
in the remodelling of the heart. In addition, Ms1 is a myofibrillar protein in 
cardiac muscle and involved in cardiac remodelling and the hypertrophic 
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response. The gene is downregulated in response towards cardiac 
remodelling. 
Following cardiac remodelling the final stage ends in heart failure.  In heart 
failure there is a disturbed mitochondrial calcium cycling, which involves 
Serca2a gene involved in removing Ca2+ into the sarcoplasmic reticulum 
during diastole. This gene is downregulated in heart failure with loss of 
function.  
To elucidate further, Ms1, Serca2a, Scn5a and UCP2 genes were chosen 
after confirming with Semi-quantitative analysis to evaluate and quantify the 
changes in the gene expression among the different treatment groups. 
Quantitative real-time PCR was done on these genes involved in different 
stages of progressive heart failure. Doxorubicin downregulated the 
expression of Ms1, Serca2a and UCP2 and upregulated the expression of 
Scn5a when compared with control. Melatonin attenuated this effect and 
restored the functionality of the genes. The data is confirmed previously by 
the Semi-quant PCR technique. The results from both these techniques are 
similar and display similar trend in gene expression in each different 
treatment groups. 
Melatonin production declines with age in rodents and humans. Lower 
circulating levels of melatonin can give arise to metabolic dysfunction in cells 
and affecting other organ systems (Reiter et al, 2017). Melatonin in the 
systemic circulation of mammals quickly disappears from the blood 
presumably due to its uptake by cells, particularly when they are under high 
oxidative stress conditions. The measurement of the subcellular distribution 
of melatonin has shown that the concentration of this indole in the 
mitochondria greatly exceeds that in the blood. Melatonin presumably enters 
mitochondria through oligopeptide transporters. Thus, melatonin is 
specifically targeted to the mitochondria where it seems to function as an 
apex antioxidant (Reiter et al, 2017). 
In the course of aging, the nocturnal melatonin peak is usually decreased, 
though with considerable inter-individual variability. Age-related reductions of 
melatonin can have different causes, a progressive deterioration of the SCN 
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in hypothalamus or of the neuronal transmission to the pineal gland (Skene 
and Swaab, 2003; Srinivasan et al, 2005). As a result, diseases and 
disorders associated with reduced melatonin secretion in humans can occur 
with age. Neurodegenerative disease (e.g. Alzheimer and Parkinson disease) 
patients have merely abolished melatonin rhythms. Amongst these 
myocardial infarction and coronary heart diseases are highly likely to occur 
with reduced levels of circulating melatonin in individuals and the most 
vulnerable are the elderly generation (Srinivasan et al, 2005; Wu and Swaab, 
2007; Hardeland, 2012). 
In such a case, melatonin may be re-considered as an adjunctive therapy to 
improve the treatment available for the diseases. In a study related with 
chronic insomnia, it was discovered that patients had associated with an 
increased risk of hypertension and elevated blood pressure. These 
individuals were treated with prolonged beta-blocker treatment, along with 
melatonin and discovered the sleep and behaviour patterns have improved 
with decreased hypertension in patients (Scheer et al, 2012; Li et al, 2015; 
Opie and Lecour, 2016). Thus, suggesting that melatonin is implicated in 
cardio protection and the molecular mechanism of such benefits may include 
decreased formation of free radicals during oxidative stress and reduced 
superoxide generation during cardiac injury.  
The effect of calcium channel blockers were investigated in primary 
hypertensive patients to observe the blood pressure profiles. However, it did 
not greatly change the blood pressure profile, being, however, less effective 
at night (Lemmer, 2007). On the other hand, calcium channel blockers (e.g. 
Verapmil) have also shown to work better at night time along with melatonin 
infusion, stimulating melatonin production and improve the efficacy/ function 
the drug by lowering blood pressure against hypertensive conditions (Zhao et 
al, 2012). 
Diez and colleagues (2013) provided evidence to suggest that 
melatonin reduced ischemia reperfusion-induced arrhythmias in rats. This 
work determined whether acute melatonin administration starting at the 
moment of reperfusion protects against ventricular arrhythmias in 
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Langendorff-perfused hearts isolated from fructose-fed rats, a dietary model 
of metabolic syndrome, and from spontaneous hypertensive rats. In both 
experimental models, there was metabolic alterations, a reduction in 
myocardial total antioxidant capacity and an increase in arterial pressure and 
NADPH oxidase activity. Melatonin initiated at reperfusion reduced the 
incidence of ventricular fibrillation from 83% to 33%. The severity of the 
arrhythmias progressively declined in melatonin-treated 
hearts. Melatonin induced a shortening of the action potential duration at the 
beginning of reperfusion and also a faster recovery of action potential 
amplitude (Diez et al, 2013). Therefore melatonin protects against ventricular 
fibrillation when administered at reperfusion, and these effects are 
maintained in hearts from rats exposed to major cardiovascular risk factors.  
MPTP opening is an important event in cardiomyocyte cell death occurring 
during ischemia-reperfusion and therefore a possible target for cardio 
protection. A study group explored whether melatonin protects heart from 
reperfusion injury by inhibiting MPTP opening, probably via prevention of 
cardiolipin peroxidation. Isolated perfused rat hearts were subjected to global 
ischemia and reperfusion in the presence or absence of melatonin in a 
Langerdoff apparatus. Melatonin treatment significantly improves the 
functional recovery of Langerdoff hearts on reperfusion, reduces the infarct 
size, and decreases necrotic damage by the reduced release of lactate 
dehydrogenase. Also, mitochondria isolated from melatonin-treated hearts 
are less sensitive than mitochondria from reperfused hearts to MPTP 
opening demonstrated by their higher resistance to Ca2+. Similar results were 
also obtained following treatment of ischemic-reperfused rat heart with 
cyclosporine A, a known inhibitor of MPTP opening. It demonstrated that 
melatonin prevents mitochondrial NAD(+) release and mitochondrial 
cytochrome c release and cardiolipin oxidation associated with ischemia-
reperfusion (Petrosillo et al, 2009). 
Early pinealectomy studies have shown that removal of the pineal gland 
reduces the mortality in animals and affects their seasonal growth in 
response to the circadian rhythms when compared to blinded study. Golden 
hamsters, especially males, blinded at 42 days of age respond with a rapid 
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increase in growth rate which varied seasonally. Seasonal response appears 
to be endogenous and not a consequence of photoperiod, temperature, age, 
sex or sexual activity. However, this response was modified by pinealectomy. 
Mortality over the 11 1/2 months of the study was increased in the 
blinded animals but was reversed by pinealectomy, where removal of the 
pineal gland had a direct effect on the mortality rate (Hoffman, 1983). 
Endogenous circulating melatonin from the pineal gland plays a vital role in 
the seasonal growth in animals and the removal of the pineal gland affects 
the circulating levels of melatonin which can decrease mortality and affect 
circadian rhythms and growth. 
Pierpaoli and Bulian (2005) investigated the relationship between 
developmental role of the pineal complex during growth, fertility, and aging 
versus time. Transplantation of a very old pineal gland (with reduced 
melatonin secretion) into the thymus or under the kidney capsule of a young 
mouse produced acceleration of aging and early death. Groups of BALB/c 
male or female mice were surgically pinealectomized at the age of 3, 5, 7, 9, 
14, and 18 months, and their life span was evaluated. Results showed that 
mice pinealectomized at younger age promoted acceleration of aging 
compared to older ages. The dominant role of the pineal in the initiation and 
progression of aging, as a death signal is clear.  The evolutionary 
development role of the pineal gland had demonstrated its control over aging 
and its importance in regulating growth (Pierpaoli and Bulian, 2005). Older 
age stimulates lower production of melatonin secreted from the pineal gland.  
Collectively, these data demonstrate the importance of melatonin in biological 
processes, health and well-being. Melatonin has shown multiple regulatory 
functions in organisms from increasing mortality to be a powerful antioxidant 
against ROS induced oxidative stress. It protects cardiomyocytes against 
cardiotoxicity induced by drugs and regulates gene expression of some key 
genes involved in the regulatory pathways of heart failure.  
In conclusion, the present thesis provided novel insight into the mechanisms 
of drug-induced mitochondrial dysfunction and apoptosis in cardiomyocytes, 
which are hallmarks of heart failure. Doxorubicin altered gene expression in 
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numerous signalling pathways associated with cardiac disease and heart 
failure. Collectively, the current results provide evidence to suggest that the 
alteration in cardiac phenotype may be caused, at least in part, by the 
changes in gene expression and these were robustly inhibited by melatonin. 
Chronopharmacology is one novel approach in the treatment of heart disease 
and cancer and the use of melatonin may confer benefits of cardio protection 
alongside drug treatments in humans. It is conceivable that melatonin may be 
used in conjunction with cardiotoxic drugs (like doxorubicin) to improve drug 
efficacy and safety. Delivering drug treatment during the night-time when 
melatonin is at its peak level may reduce the severity of early-onset cardiac 
dysfunction and future development of heart failure. Thus, co-treatment with 
melatonin may provide a new platform for intervention for cancers and heart-
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Samples Concentration  




amount       
(µg/20µl) 
µl of each 
sample 
containing 











Control 267.4 1.94 5.35 3.74 1 7.26 
Control 283.2 1.95 5.66 3.53 1 7.47 
Control 251.3 1.96 5.03 4.00 1 7.00 
Dox 196.3 1.88 3.93 5.10 1 5.90 
Dox 231.3 1.85 4.63 4.33 1 6.67 
Dox 120.3 1.82 2.41 8.30 1 2.70 
Dox+Mel 128 1.83 2.56 7.80 1 20.8 
Dox+Mel 187 1.88 3.74 5.35 1 5.65 
Dox+Mel 156 1.84 3.12 6.41 1 4.59 
Mel 190 1.90 3.80 5.26 1 5.74 
Mel 265.4 1.92 5.30 3.80 1 7.20 






Table 2: Image J quantification of Cav3 gene expression and the ratio of 
Cav3 expression standardised by Cyclo A. 
 
 
Sample Cav3 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Cav3 mRNA 
/Cyclo A mRNA 
ratio 
Control 4665.983 4846.36 0.96 
Control 7277.882 4060.94 1.79 
Control 8356.418 4819.60 1.73 
Dox+Mel 712.527 4889.31 0.15 
Dox+Mel 1968.497 4654.59 0.42 
Dox+Mel 2201.548 4634.18 0.48 
Dox 266.092 4863.31 0.05 
Dox 291.678 4387.06 0.07 
Dox 1223.255 4732.89 0.26 
Mel 5702.397 5108.13 1.12 
Mel 5161.619 5092.01 1.01 




Table 3: Image J quantification of Drp1 gene expression and the ratio of Drp1 
expression standardised by Cyclo A. 
 
Sample Drp1 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Drp1 mRNA 
/Cyclo A mRNA 
ratio 
Control 6023.45 4846.36 1.24 
Control 5185.98 4060.94 1.28 
Control 4791.35 4819.60 0.99 
Dox+Mel 3081.74 4889.31 0.63 
Dox+Mel 5685.10 4654.59 1.22 
Dox+Mel 3511.45 4634.18 0.76 
Dox 3139.86 4863.31 0.65 
Dox 1783.96 4387.06 0.41 
Dox 1710.55 4732.89 0.36 
Mel 5482.62 5108.13 1.07 
Mel 2387.62 5092.01 0.47 




Table 4: Image J quantification of Mfn1 gene expression and the ratio of 
Mfn1 expression standardised by Cyclo A. 
 
 
Sample Mfn1 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Mfn1 mRNA 
/Cyclo A mRNA 
ratio 
Control 2793.81 4846.36 0.58 
Control 5124.18 4060.94 1.26 
Control 4431.64 4819.60 0.92 
Dox+Mel 3296.74 4889.31 0.67 
Dox+Mel 4666.69 4654.59 1.00 
Dox+Mel 2059.28 4634.18 0.44 
Dox 2302.45 4863.31 0.47 
Dox 1317.01 4387.06 0.30 
Dox 1848.13 4732.89 0.39 
Mel 2937.50 5108.13 0.58 
Mel 3413.28 5092.01 0.67 




Table 5. Image J quantification of PPAR-ƴ gene expression and the ratio of 
PPAR-ƴ expression standardised by Cyclo A. 
 
Sample PPAR-ƴ mRNA 
abundance 
Cyclo A mRNA 
abundance 
PPAR-ƴ mRNA 
/Cyclo A mRNA 
ratio 
Control 4045 4056 1.00 
Control 4495 3029 1.48 
Control 6484 4204 1.50 
Dox+Mel 3085 3632 0.85 
Dox+Mel 3050 3726 0.82 
Dox+Mel 3755 3102 1.20 
Dox 1472 4820 0.30 
Dox 1587 2863 0.50 
Dox 1491          2955 0.50 
Mel 4530          4030 1.12 
Mel 5047          3085 1.60 




Table 6: Image J quantification of Parp 1 and Parp 2 gene expression and 















/Cyclo A mRNA 
ratio 
Control 10646.96 11698.28 4846.36 2.20 2.41 
Control 11835.96 9242.69 4060.94 2.91 2.28 
Control 10849.50 11017.98 4819.60 2.25 2.29 
Dox+Mel 11579.84 9392.28 4889.31 2.37 1.92 
Dox+Mel 12442.21 9327.05 4654.59 2.67 2.00 
Dox+Mel 10421.67 7093.15 4634.18 2.25 1.53 
Dox 1852.70 4065.98 4863.31 0.38 0.84 
Dox 4145.01 2768.52 4387.06 0.94 0.63 
Dox 4260.18 5365.88 4732.89 0.90 1.13 
Mel 8338.18 9517.61 5108.13 1.63 1.86 
Mel 8914.15 9307.73 5092.01 1.75 1.83 
Mel 8034.32 10612.78 5059.31 1.59 2.10 
 
 
Table 7: Image J quantification of Sirt3 gene expression and the ratio of Sirt3 
expression standardised by Cyclo A. 
Sample Sirt3 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Sirt3 mRNA /Cyclo 
A mRNA ratio 
Control 3120 4056 0.77 
Control 4288 3029 1.42 
Control 3964 4204 0.95 
Dox+Mel 11174 3632 3.08 
Dox+Mel 9071 3726 2.44 
Dox+Mel 8825 3102 2.85 
Dox 5628 4820 1.16 
Dox 2979 2863 1.04 
Dox 7218 2955 2.44 
Mel 7413 4030 1.84 
Mel             5157              3085 1.67 




Table 8: Image J quantification of Bcl-2 gene expression and the ratio of Bcl-
2 expression standardised by Cyclo A. 
  
Sample Bcl-2 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Bcl-2 mRNA /Cyclo 
A mRNA ratio 
Control 9202 4056 2.3 
Control 10181 3029 3.3 
Control 11466 4204 2.73 
Dox+Mel 541 4820 1.5 
Dox+Mel 323 2863 1.12 
Dox+Mel 892            2955 0.83 
Dox 5121            3632 0.11 
Dox 4185            3726 0.11 
Dox 2566            3102 0.30 
Mel 15228            4030 3.78 
Mel 11703            3085 3.79 





Table 9: Image J quantification of Bcl-xL gene expression and the ratio of 
Bcl-xL expression standardised by Cyclo A. 
 
Sample Bcl-xL mRNA 
abundance 
Cyclo A mRNA 
abundance 
Bcl-xL mRNA 
/Cyclo A mRNA 
ratio 
Control 4867 4056 1.2 
Control 3635 3029 1.2 
Control 6306 4204 1.5 
Dox+Mel 14339 4820 1.5 
Dox+Mel 11178 2863 1.8 
Dox+Mel 9306          2955 1.6 
Dox 7230 3632 2.8 
Dox 5153 3726 3 
Dox 4728 3102 3 
Mel 7254           4030 1.8 
Mel 4936             3085 1.6 
Mel 4232           2821 1.5 
 
 
   





Table 10: Image J quantification of Ucp2 gene expression and the ratio of 
Ucp2 expression standardised by Cyclo A. 
 
Sample Ucp2 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Ucp2 mRNA /Cyclo 
A mRNA ratio 
Control 5320 4056 1.31 
Control 6023 3029 1.98 
Control 5768 4204 1.39 
Dox+Mel 6033 3632 1.66 
Dox+Mel 5051 3726 1.36 
Dox+Mel 3703 3102 1.2 
Dox 2442 4820 0.5 
Dox 1632 2863 0.57 
Dox 2633 2955 0.9 
Mel 10560 4030 2.62 
Mel 8886             3085 2.88 





Table 11: Image J quantification of Ms1 gene expression and the ratio of Ms1 
expression standardised by Cyclo A. 
Sample Ms1 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Ms1 mRNA /Cyclo 
A mRNA ratio 
Control 4957.08 4846.36 1.02 
Control 6249.10 4060.94 1.54 
Control 7204.59 4819.60 1.49 
Dox+Mel 2665.84 4889.31 0.55 
Dox+Mel 4671.91 4654.59 1.00 
Dox+Mel 2023.48 4634.18 0.44 
Dox 647.53 4863.31 0.13 
Dox 920.94 4387.06 0.21 
Dox 1582.94 4732.89 0.33 
Mel 6585.98 5108.13 1.29 
Mel 5279.03 5092.01 1.04 






Table 12: Image J quantification of Scn5a gene expression and the ratio of 
Scn5a expression standardised by Cyclo A. 
 
Sample Scn5a mRNA 
abundance 
Cyclo A mRNA 
abundance 
Scn5a mRNA 
/Cyclo A mRNA 
ratio 
Control 506.46 4846.36 0.10 
Control 313.87 4060.94 0.08 
Control 3540.72 4819.60 0.73 
Dox+Mel 796.11 4889.31 0.16 
Dox+Mel 1399.94 4654.59 0.30 
Dox+Mel 448.82 4634.18 0.10 
Dox 4596.31 4863.31 0.95 
Dox 4476.38 4387.06 1.02 
Dox 3377.79 4732.89 0.71 
Mel 772.48 5108.13 0.15 
Mel 732.04 5092.01 0.14 





Table 13: Image J quantification of Serca2a gene expression and the ratio of 
Serca2a expression standardised by Cyclo A. 
 
Sample Serca2a mRNA 
abundance 
Cyclo A mRNA 
abundance 
Serca2a mRNA 
/Cyclo A mRNA 
ratio 
Control 8249.52 4846.36 1.70 
Control 8666.64 4060.94 2.13 
Control 8792.71 4819.60 1.82 
Dox+Mel 5973.64 4889.31 1.22 
Dox+Mel 8826.59 4654.59 1.90 
Dox+Mel 7024.74 4634.18 1.52 
Dox 3854.33 4863.31 0.79 
Dox 3794.15 4387.06 0.86 
Dox 7433.98 4732.89 1.57 
Mel 8044.40 5108.13 1.57 
Mel 10416.76 5092.01 2.05 







Table 14: Image J quantification of Myh7 gene expression and the ratio of 
Myh7 expression standardised by Cyclo A. 
Sample Myh7 mRNA 
abundance 
Cyclo A mRNA 
abundance 
Myh7 mRNA /Cyclo 

































































Alamar Blue cell viability assay 
 
Table 15: Experiment 1 representing % cell viability for doxorubicin and       
melatonin. 
 
Control Dox Dox+Mel Mel 
101 70.5 100 82 
103 70 99 81 
103 71.1 98.2 84.4 
95 71.1 104 116 
102 73.4 104 116.6 
98.2 72.6 101 85.1 


















































Figure 1: Experiment 1: Melatonin blocked doxorubicin-induced cell 
death in H9c2 cells. Cells were treated with DOX (0.5µM) with and without 
MEL (1µM) for 24hr. Data are presented as mean ± SEM (n=5 separate 
experiments; each experiment had 3 to 10 samples). One Way Anova: F (3, 
25) = 21.3, P< 0.0001. Data considered statistically significant. 
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Table 16: Experiment 2 representing % cell viability for doxorubicin and       
melatonin. 
 
Control Dox Dox+Mel Mel 
83.5 59 102 113 
86 57 100 113 
87 57 100 118 
143 61.3 107 98.7 
98 57.5 108 100 
100 57 103 101 
























































Figure 2: Experiment 2: Melatonin blocked doxorubicin-induced cell 
death in H9c2 cells. Cells were treated with DOX (0.5µM) with and without 
MEL (1µM) for 24hr. Data are presented as mean ± SEM (n=5 separate 
experiments; each experiment had 3 to 10 samples). One Way Anova: F (3, 
27) = 25.03, P< 0.0001. Data considered statistically significant. 
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Table 17: Experiment 3 representing % cell viability for doxorubicin and       
melatonin. 
 
Control Dox Dox+Mel Mel 
95 81.8 92.5 87.3 
105.4 84 93.7 89.2 
107 82.6 94.3 100 
107.8 83.7 92.8 102.8 























































Figure 3: Experiment 3: Melatonin blocked doxorubicin-induced cell 
death in H9c2 cells. Cells were treated with DOX (0.5µM) with and without 
MEL (1µM) for 24hr. Data are presented as mean ± SEM (n=5 separate 
experiments; each experiment had 3 to 10 samples). One Way Anova: F (3, 
19) = 13.56, P< 0.0001. Data considered statistically significant. 
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Table 18: Experiment 4 representing % cell viability for doxorubicin and 
melatonin. 
 
Control Dox Dox+Mel Mel 
98 71.4 92.4 90 
92.3 76 95.2 93 
109 77.6 100 90  














































Figure 4: Experiment 4: Melatonin blocked doxorubicin-induced cell 
death in H9c2 cells. Cells were treated with DOX (0.5µM) with and without 
MEL (1µM) for 24hr. Data are presented as mean ± SEM (n=5 separate 
experiments; each experiment had 3 to 10 samples). One Way Anova: F (3, 






Table 19: Experiment 5 representing % cell viability for doxorubicin and 
melatonin. 
 
Control Dox Dox+Mel Mel 
99 61.7 96.2 107 
101 61.3 88 98.6 
100 64.6 95 96  
64.6 92.3 96.2  


















































Figure 5: Experiment 5: Melatonin blocked doxorubicin-induced cell 
death in H9c2 cells. Cells were treated with DOX (0.5µM) with and without 
MEL (1µM) for 24hr. Data are presented as mean ± SEM (n=5 separate 
experiments; each experiment had 3 to 10 samples). One Way Anova: F (3, 
16) = 104.7, P<0.0001. Data considered statistically significant. 
 
 
